ZA200607668B - Imidazole derivatives used as tafia inhibitors - Google Patents
Imidazole derivatives used as tafia inhibitors Download PDFInfo
- Publication number
- ZA200607668B ZA200607668B ZA200607668A ZA200607668A ZA200607668B ZA 200607668 B ZA200607668 B ZA 200607668B ZA 200607668 A ZA200607668 A ZA 200607668A ZA 200607668 A ZA200607668 A ZA 200607668A ZA 200607668 B ZA200607668 B ZA 200607668B
- Authority
- ZA
- South Africa
- Prior art keywords
- twice
- alkyl
- unsubstituted
- once
- substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 5
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title description 2
- 150000002460 imidazoles Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- -1 cyclic amine Chemical class 0.000 claims description 103
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 69
- 125000003118 aryl group Chemical group 0.000 claims description 65
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 65
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 47
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 41
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000006413 ring segment Chemical group 0.000 claims description 21
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 19
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 13
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 12
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 12
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 150000004051 azocanes Chemical class 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 7
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims description 6
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims description 6
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 6
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 6
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 6
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 6
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 6
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims description 5
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 5
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 claims description 5
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- 150000001537 azepanes Chemical class 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000015271 coagulation Effects 0.000 claims description 5
- 238000005345 coagulation Methods 0.000 claims description 5
- PPSZHCXTGRHULJ-UHFFFAOYSA-N dioxazine Chemical compound O1ON=CC=C1 PPSZHCXTGRHULJ-UHFFFAOYSA-N 0.000 claims description 5
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 5
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 5
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims description 5
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 4
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 4
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 4
- MSRJJSCOWHWGGX-UHFFFAOYSA-N 2h-1,3-diazepine Chemical compound C1N=CC=CC=N1 MSRJJSCOWHWGGX-UHFFFAOYSA-N 0.000 claims description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 2
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 2
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims description 2
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 125000002785 azepinyl group Chemical group 0.000 claims description 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004069 aziridinyl group Chemical group 0.000 claims description 2
- 125000004623 carbolinyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical group O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims description 2
- 125000005438 isoindazolyl group Chemical group 0.000 claims description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 201000005665 thrombophilia Diseases 0.000 claims description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 46
- 235000013350 formula milk Nutrition 0.000 claims 38
- 229940095574 propionic acid Drugs 0.000 claims 24
- 235000019260 propionic acid Nutrition 0.000 claims 22
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 13
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 4
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 235000017168 chlorine Nutrition 0.000 claims 3
- 229940060038 chlorine Drugs 0.000 claims 3
- 229940113083 morpholine Drugs 0.000 claims 3
- JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- JPPREFOETTUXDK-UHFFFAOYSA-N 1h-1,3-diazepine Chemical compound N1C=CC=CN=C1 JPPREFOETTUXDK-UHFFFAOYSA-N 0.000 claims 1
- OVRMEGOFIXQTHY-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-(1-prop-2-ynylimidazol-4-yl)propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C1=CN(CC#C)C=N1 OVRMEGOFIXQTHY-UHFFFAOYSA-N 0.000 claims 1
- SQPQZHRORMHFGV-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[4-(propylcarbamoylamino)phenyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(NC(=O)NCCC)=CC=C1N1C=C(C(CC=2C=NC(N)=CC=2)C(O)=O)N=C1 SQPQZHRORMHFGV-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 230000005526 G1 to G0 transition Effects 0.000 claims 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 235000018259 Solanum vestissimum Nutrition 0.000 claims 1
- 240000002825 Solanum vestissimum Species 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- CJYXCQLOZNIMFP-UHFFFAOYSA-N azocan-2-one Chemical group O=C1CCCCCCN1 CJYXCQLOZNIMFP-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- XXUJMEYKYHETBZ-UHFFFAOYSA-N ethyl 4-nitrophenyl ethylphosphonate Chemical compound CCOP(=O)(CC)OC1=CC=C([N+]([O-])=O)C=C1 XXUJMEYKYHETBZ-UHFFFAOYSA-N 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 229940028332 halog Drugs 0.000 claims 1
- 210000004394 hip joint Anatomy 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 210000000629 knee joint Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 claims 1
- 150000003548 thiazolidines Chemical class 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229960005141 piperazine Drugs 0.000 description 3
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- RVNSAAIWCWTCTJ-ZPQYLTHOSA-N (2s,3s,4r)-2-(1,2-dihydroxyethyl)pyrrolidine-3,4-diol Chemical compound OCC(O)[C@@H]1NC[C@@H](O)[C@H]1O RVNSAAIWCWTCTJ-ZPQYLTHOSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 241000156724 Antirhea Species 0.000 description 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 241000135164 Timea Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002669 lysines Chemical group 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000000019 pro-fibrinolytic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
@® 1
IMIDAZOLE DERIVATIVES LJSED AS TAFIA INHIBITORS
The invention relates to novel compounds o¥ the formula | which inhibit the enzyme
TAFla (activatted thrombin-activatable fibrinolysis inhibitor), to process fer their preparation ard to the use thereof as medic aments.
The enzyme WAFla is produced for example= through thrombin activatior from the thrombin-activwatable fibrinolysis inhibitor zymogen (TAF). The enzyme TAFI is also referred to as plasma procarboxypeptidase BB, procarboxypeptidase U o»r procarboxype ptidase R and is a proenzyme similar to carboxypeptidase= B (L.. Bajzar,
Arterioscler. T hromb. Vasc. Biol. 2000, pageas 2511 — 2518).
During formation of a clot, thrombin is generated as the final product of the coagulation cascade and Enduces conversion of soluble plasma fibrinogen to an insoluble fibrin matrix. At the same time, thrombin activates the endogenous fibrinolysis inhibitor TAF.
Activated TAI (TAFIa) is thus produced during thrombus formation and lysis from the zymogen TAF through the action of thromb in; thrombomodulin in a cormplex with thrombin incresases this effect about 1250-fold. TAFla cleaves basic am ino acids at the carboxy end of fibrin fragments. The loss of carboxy-terminal lysines ass binding sites for plasminogen then leads to inhibition of fibrirmolysis. Efficient inhibitors of TAFla prevent the loss of thease high-affinity lysine binding sites for plasminogen and, i n this way, assist endogenous fibrinolysis by plasmin: TAFla i nhibitors have profibrinolytic effects.
In order to mazintain hemostasis in the blood, mechanisms which lead to the clotting of blood and to the breaking up of clots have d eveloped; these are in equilibrium. If a disturbed equmilibrium favors coagulation, fib xin is produced in larger quantities, so that pathological forocesses of thrombus formation may lead to serious pathological states in humans.
Just like exces=ssive coagulation may lead to serious pathological states caused by thrombosis, aan antithrombotic treatment entails the risk of unwanted bleeding through disturbance oef the formation of a necessary hemostatic plug. Inhibition «f TAFla increases encdogenous fibrinolysis - without influencing coagulation and platelet aggregation - i.e. the disturbed equilibrium iss shifted in favor of fibrinolysis. It is thus possible both to counter the buildup of a clirically relevant thrombus, ard to increase the lysis of a pre—existing clot. On the other hana, buildup of a hemostatic p lug is not
® impaired, so that a hemorrhagic diathesis is probably rot to be expected (Bourmna et al.,
J. Thrombosis and Haemeostasis, 1, 2003, pages 1566 - 1574).
Inhibitors of TAFia have already been described in the international application s WOO03/013526 and WO033/061653.
The TAF la inhibitors of th € invention are suitable for a prophylactic and for a th erapeutic use in humans suffering fwom disorders associated witk thromboses, embolism s, hypercoagulability or fibrostic changes. They are suitabl e both for acute and for long-term 1.0 therapy.
The invention therefore realates to a compound of the formula
X
SE © z—0 u N
LS and/or all stereoisomeric Forms of the compound of the formula | and/or mixtures of these forms in any ratio, &and/or a physiologically tolera ted salt of the compound of the formula |, where
Uis 1) hydrogen atom, 2) -(C1-Cg)-ali=y, 3) -(C3-Cg)-cy cloalkyl, 4) fluorine, 5) -O-CF3 or 6) -CF3, »s5 Xis the radical of the formula Il -(A1)m-A2 {I} in which m is the integer zero ©r 1, .
Atis 1) -(CH=)x- in which n is the integer 1, 2 or 3, or 2) -O-(CH2)p- in which n is the integesr zero, 1, 2 or 3,
A2is 1) 4-to 15-membered Het ring in whi ch Het ring comprises a®t least one MN atom and is substituted by &an amino group and maw
® additionally be substituted ind ependently of one another orice, twice or three times by a -(C4-Cg3)-alkyl, halogen, -CF3 or -O-CIF3, 2) -(C4-Cg)-alkyl-NH»o or 3D -(C3-Cg)-cycloalkyl-NHa,
Yis 1) the radiczal of the formula ill
A3-(Ad)o-(AS)p (mn where a) A 3is -(C3-Cg)-cycloalky! or -(C2-Cg)-alkynylene, in which cycloal kyl or allkynylene is unsubstituted or substituted independently of one arother omce, twice or three times by -O-R10 or R1,
A 4 is -N(R2)2- in which R2 is as defined below, and the two R2 radicals ame defined independently of one ancther,
A 5is absent, ois the integer zero or 1, and
R_10 is a hydrogen, -(C4-Cg)-alkyl or -(Cg-C14)-aryl, b) A 3is -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or sLbstituted insdependently of one another once, twice or three times by -O-R1 0 or R1,
Ad is -N (R2)-, and
ASis ad1) -C(O)-R3, ad2) -C(O)-N(R4)-R5, ad3) -(SO2)-R6, or aD4) -C(O)-O-R7, : ois the imteger 1, and p is the imteger 1, c) Ais cyclic amine having 3 to 8 ring atoms in which cyclic amine &s ursubstituted or substituted independently of one another once, tice or tharee times by R1,
A4 and A\5 are as defined under b), where AS is bonded to the N atom of A3, o is the imnteger zero, and p is the imteger zero or 1, or d) AZZ is -(CH2)q-(Cg-C14)-aryl in which aryl is unsubstituted or substituted in dependently of one another once, twice or three times by R1,
A4 and M5 are as defined under b), o is the irteger zero or 1, and
® p is the integer 1, and gis the integer zero, 1, 2or 3, e) A3 is -{CHo)-Hest in which Het is a 4- to 15-m embered Het ring, and Het ring is unsubstituted or substituted independe ntly of one another oncze, twice or three tirmes by = O or R1,
A4 and A5 are as defin ed under b), o is the integer zero or 1, p is the integer 1 and ris the integer zero, 1, 2or 3, f) A3is +(CH2)g-(Cp-C14)-ary! in which aryl is umsubstituted or substitiated independently o f one another once, twice or three times by R1,
Ad is -O-,
AS is -(Cg-C44)-aryl in which aryl is unsubstituted or substituted independe=ntly of one another once, twice or three times by R1 0 and p are the integer- 1 and q is the integer zero, 1, 2 or 3, 9) -CH(-(Ce-C14)-aryl)-(Cg-C14)-aryl, where R1 is a) -(Cg-C14)-aryl, where aryl is unsubstituted or- substituted independe=ntly of one another once, twice or three times by -(C¢-Cg)-alkyl, -(Cg-C4)-axalkyl- (C3-Cg)-cycloal kyl, -CF3, =O, -O-CF3 or halegen, b) 4- to 15-membesred Het ring, c) -(C1-Cg)-alkyl, d) -(Co-C4)-alkyl-( C3-Cg)-cycloalkyl, e) -CF3, f) -O-CFj or a) halogen, where R2 is a) -(Cg-C14)-ary! 3n which aryl is unsubstituted =or substituted indepencdently of one another once, twice or three times by R1, b) -(C4-Cg)-alkyl i n which alkyl is unsubstituted or substituted indepen dently of one another once, twice or three times by R1,
® c) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R 1, d) -CF3 or e) hydrogen atom, 5 where R3, R6 and R7 are identical or different are independemtly of one another a) -(C4-Cg)-alkyl in which alkyl is unsubstituted or substitmuted independently of one another once, twice or three times by R1, b) -(Cg-C14)-aryl in which aryl is unsubstituted or substitLited independently of one another once, twice or three times by R1, c) 4- to 15-membered Het ring in which Het ring is unsubstituted or substituted independently of one another once, twice or three times by R1, d) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R71, or e) hydrogen atom, 1= where R4 and RS are identical or different are independently of one another a) -(C4-Cg)-alkyl or =(C,-Cyp)-alkenyl, in which alkyl! or alkeenyl is unsubstituted or substituted independently of one another once, twice or three times by R1, b) -(Cg-C14)-aryl in which aryl is unsubstituted or substitu ted independently of one another once, twice or three times by R1, c) 4- to 15-membered Het ring in which Het ring is unsubstituted or substituted independently of one another once, twice or three times by R1, d) -(C3-Cg)-cycloalky! in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three timess by R1, or 2s e) hydrogen atom, or
R4 and RS form together with the nitrogen atom to which they are bonded a ring having 3 to 8 ring atoms which may, in addition to the nitrogen atom, also comprise one to two additional heteroatoms from t#he series oxygen, sulfur or nitrogen, 30s Yis 2)the radical of the formula IV, 0] N R8 1-5 where R8 is
® a) -(C + -Cg)-alkyl in which alkyl is unstbstituted or substitute=d inde=pendently of one another once, twice or three times by R1, b) -(Ce5-C14)-aryl in which ary! is unsubstituted or substitute=d indespendently of one another once , twice or three times Tby R1, c) 4- tao 15-membered Het ring in which Het ring is unsubstituted or submstituted independently of one arother once, twice or three times by R1, d) -(C-3-Cg)-cycloalky! in which cycloalkyl is unsubstituted or substituted independently of one a nother once, twice or three times by R1, or e) hydrogen atom,
Yis 3) the radical of the formula V oO
R15 R17 WR ba fg | v) 2 fo R13
R18 R18 where in case a)
R12is 1) -(C 1-Cg)-alkyl in which alkyl is uns ubstituted or substitut.ed independently of one another once, twice or three times by R1, 2) -(C o-C3)-alkyl-(C3-Cg)-cycloalkyl iwn which cycloalkyl is unsubstitumted or substituted independenti=y of one another once-, twice or three time=s by R1, 3) -(Cg-C3)-alkyl-(Cg-C14)-aryl in which aryl is unsubstituted or substitutead independently of one another once, twice or three ti mes by R1, or 4) -(C&-C3)-alkyl-Het in which Het is wunsubstituted or substituted ind ependently of one another once, twice or three times by R1, and
R13is 1) -(C-Ca)-alkyl-(Cg-C14)-ary! in wh ich alkyl and aryl are e=ach unsubstituited or substituted independent] y of one another once, twice or three time2s by R1, or 2) -(C-Cjy)-alkyl-Het in which alkyl and Het are each unsubstituted or substitute d independently of one another once, twice or three ti mes by R1, where in case b)
R12is1) hydrogen atom,
® 2) -(C1-Cg)-alkyl in which alkyl is wunsubstituted or substituted independently of one another once, tw~ice or three times by R1, 3) -(Cp-C3)-alkyl-(Cg-C14)-aryl in which aryl is unsubstituted cr sub stituted independently of one another once, twice or three time=s by R1, or 4) -(Cp-C3)-alkyl-Het in which Het: is unsubstituted or substitufted indeependently of one another once, twice or three times by R1, an d
R13 is -CH(R8)-R9 where R8 and R9 are indespendently of one another -(Ces-C14)-aryl or Het in which Het and aryl are each unsubstituted or sub stituted independently of one another once, twice or three time=s by -O-€C1-C4)-alkyl or R1 and
R16, R17, R18 and R19 are identical or differ-ent and are independently of one another 1) hydrogen atom, 2) -(C1-Cg)-alkyl, in which alkyl is unsubstituted or substituted once or twice by R1, 3) halogen, 4) -OH, 5) -NH2, 6) -(Cp-C3)-alkyl-(Cg-C14)-aryl in which alkyl and aryl are each unsubstituted or substituted ind ependently of one another once, twice or three times by R1, or 7) -(Cg-C3)-alkyl-Het in which alkyl and Het are each unsubstituted or substituted independently of on e another once, twice or three times by R1, or
R16 and R 17 or R18 and R19 form together with the carbon atom to which they are respectively bonded a ring having 3 to 6 ring atoms, or
Yis 4) the radical of the formula Vi,
R27 Na R24 — oa ‘ros (VI) os Reo
® wher~e
R24 and R25 are identical or differ ent and are independently «of one another 1) hydrogen atom, 2) -(C4-Cg)-alkyl in which alkyl! is unsubstituted or substituted once or twice by R1, 3) -(Cp-C3)-alkyl-(Cg-C=14)-ary! in which alkyl and aryl are each unsubstituted or substituted independently of ore another once, twice or three times by R1, 4) -(Cp-C3)-alkyl-Het in which alkyl and Het are eaach unsubstituted or substituted independ ently of one another once, twice or three times by R1, or 5) -(Cp-C3)-alkyl-(C3-C g)-cycloalkyl, or
R24 and R25 form together with th e nitrogen atom to which they are bonded a ring Bhaving 3 to 8 ring atoms whichs may, in addition to the nitrogen atom, also comprise one to two additional hetesroatoms from the series oxygen, sulfur or nitroggen,
R26, R27, R28 and R29 are identical or different and are inde=pendently of one anotker 1) hydrogen atom, 2) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted once or twice by R1, 3) halogen, 4) -OH, 5) -NHo, 6) -(Cg-C3)-alkyl-(Cg-C 44)-aryl in which alkyl and aryl are each unsubstituted or subsstituted independently of ore another once, twice or three times toy R1, or 7) -(Cp-Cgy)-alkyl-Het in which alkyl and Het are ea ch unsubstituted or substituted independently of one another once, twice or three times by R1, or
R26 and R2 7 or R28 and R29 form togeth er with the carbon atom to which they are respectively bonded a ring having 3 to 6 rieng atoms,
Zis 1) hydrogen atom, 2) -(C1-Ceg)-alkyl,
® 3) (C1-Cg)-alkyl-OH, 4) -(Cg-C4)-alkyl-(C3-Cg)-cycloalkyX, 5) -(C1-C1g)-alkyl-O-C(0O)-O-R1, 6) -(CH2)~(Cg-C14)-aryl in which a ryl is unsubstituted or substitu ted independently of one another on ce, twice or three times by R1 , and ris the integer zero, 1, 2 or 3, or 7) -(CHo)g-Het in which Het is unsubstituted or substituted indepesndently of one another once, twice or three times by R1, and s is the inte ger zero, 1, 2o0r3.
The invention further relates to the compound of the formula la
X fo) SA) N= (ja) z—0 YU NT where
Uis 1) hydrogen atom, 2) -(C1-Cg)-alkyl, 3) -(C3-Cg)-cycloalkyl, 4) fluorine, 5) -O-CF3 or 6) -CF3,
Xis thes radical of the formula Il in which m is the integer zero or 1,
A1 is 1) -(CH2)pn- in which nis the integer 1, 2 or 3, or 2) -O-(CH2)p- in which n is the integer zero, 1, 2 or 3,
AZ is 1) 4- to 15-membered Het ri ng in which Het ring is selected from the group of acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazal inyl, benzimidazolyl, carbolinyl, quina. zolinyl, quinolinyl, 4H-quinolizEnyl, quinoxalinyl, quinuclidinyl, chronmanyl, chromenyl, cinnolinyl, deeca- hydroquinolinyl, imidazolidinyl, irmidazolinyl, imidazolyl, 1H-inda&zolyl, indolinyl, indolizinyl, indolyl, 3H-i ndolyl, isobenzofuranyl, isochr-omanyl, isoindazolyl, isoindolinyl, isoindo lyl, isoquinolinyl (benzimidazo yl), isothiazolidinyl, 2-isothiazolinyl, i sothiazolyl, isoxazolyl, isoxazcolidinyl, 2- isoxazolinyl, morpholinyl, naphtheyridinyl, octahydroisoquinolinywl,
® osxadiazolyl, 1,2,3-oxadiazolyl, 1, 2 4-oxadiazolyl, 1,2,5-oxa diazolyl, 1 ,3,4-oxadiazolyl, oxazolidinyl, o xazolyl, pyrimidinyl, phenaanthridinyl, pshenanthrolinyl, phenazinyl, phe nothiazinyl, phenoxathiiny~l, phenoxazinyl, pshthalazinyl, piperazinyl, piperidi nyl, pteridinyl, puryny!, pymranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyraz olyl, pyridazinyl, pryidoox&azolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridiny=l, pyridyl,
Pyrimidinyl, pyrrolidinyl, pyrroliny=!, 2H-pyrrolyl, pyrrolyl, teetrahydroisoquinolinyl, tetrahydmroquinolinyl, tetrahydropyr idinyl, 6H-1,2,5- thhiadazinyl, 1,2,4-thiadiazolyl, 1, 2 5-thiadiazolyl, 1,3,4-thia=diazolyl, tlhianthrenyl, thiazolyl, thienothia zolyl, thienooxazolyl, thiernoimidazolyl, t hiomorpholinyl, triazinyl, 1,2,3-tmriazolyl, 1,2,4-triazolyl, 1,22,5-triazolyl, 4 .3,4-triazolyl and xanthenyl and in which the Het ring is substituted by an amino group and may additionallly be substituted indepencdently of one another once, twice or three timees by a -(C1-C3)-alkyl, halogen, -CF3 or —
O-CF3, 2) -(C41-Cg)-alkyl-NH2 or 3) -(C3-Cg)-cycloalkyl-NH2,
Y is M)the radical of the formula lll wshere 2) A3 is -(C3-Cg)-cycloalkyl or -(C2-Cg)-alkynylene in which cycloalkyl or alkylnylene is unsubsti tuted or substituted indepe=endently of one another once, twice or three times by R1,
Ad is —-N(R2)o- in which FR2 is as defined below, arad the two R2 radicals are defined indegoendently of one another,
AS5 is absent and ois the integer zero or 1, bo) A3 is -(C3-Cg)-cycloalkyl in which cycloalkyl is uns ubstituted or substituted independently of one another once, twi ce or three times by R1,
Ad is—N(R2)-, and
A5is a)1) -C(O)-RS3, a)2) -C(O)-N(R=4)-RS5, a)3) -{SO2)-R6. or a)d) -C(0O)-O-R77, ois the integer 1, and
® p is the integer 1, c) A3 is cyclic amine from the group of propylamine, azetidine, pyrrolidine, piperidine, azepanes or azocanes, in which cyclic am ine is unsubstituted or substitu ted independently of one another once2, twice or three times by R1,
Ad and A5 are as defined under b), where AS is bonded to the N atom of A3, o is the integer zero, and : p is the integer zero or 1, or d) A3 is -(CH2)q-(Cg-C14)-arylin which aryl is selected from the grosup of phenyl, naphthyl, anthryl or fluoreny! and is unsubstituted or substituted independently of one another once, twice or three time=s by R1,
A4 and AS are as defined under b) o is the integer zero or 1, and p is the integer 1, and q is the integer zero, 1, 2 or 3, e) A3 is -(CH2)-Het in which Het is as defined above and is unsubstituted or substituted independently of one another once, twice or three times by =O or R1,
A4 and AS are as defined under b), ois the integer zero or 1, p is the integer 1 and ris the integer zero, 1, 2 or 3, f) A3 is -(CH2)q-(Cg-C14)-aryl in which is aryl is unsubstituted or substituted independently of one another once, twice or three times by R1,
Ad is -O-,
AS5 is -(Cg-C14)-aryl in which aryl is unsubstituted or substituted independently of one another once, twice or three times by R1, o and p are the integer 1 and q is the integer zero, 1, 2 or 3, g) -CH(phenyl)-phenyl, where R1 is
- ® a) -(Cg-C14)-aryl in which aryl is as defined above and in which aryl is unsubstituted or iss substituted independently of one another once, twice or three timeas by -(C4-Cg)-alkyl, -(Co-C=)-alkyl-(C3-Cs)- cycloalkyl, -CF3, =O, -O—CF3 or halogen b) 4- to 15-membered Het ring in which Het is amas defined above, c) -(C1-Cg)-alkyl, d) -(C3-Cg)-cycloalk vl, e) -CF3, f) -O-CF3 or g) halogen, wwhere R2 is a) -(Cg-C14)-ary! in which aryl is as defined above and is unsubstituted or saubstituted independently of one another once, twice or thre=e times by R1, b) -(C1-Cg)-alkyl in wohich alkyl is unsubstituted cr substituted oo independently of o»ne another once, twice or three times by
R1,
C) -(C3-Cg)-cycloalky~l in which cycloalkyl! is unsumbstituted or substituted independently of one another once, twice or three times by R1, d) -CF3 or e) hydrogen atom, where R3, R6 and R7 are identic al or different are independ ently of one armother a) -(C4-Cg)-alkyl in which alkyl is unsubstituted o r substituted independently of ore another once, twice or th-ree times by
R1, b) -(Cg-C14)-aryl in which aryl is as defined abov e and is unsubstituted or su bstituted independently of cone another once, twice or three times by R1,
® c) 4- to 15-membered Het ri ng in which Het ring is ass defined above and is unsubstitute=d or substituted indepenedently of one another once, twice or three times by R1, d) -(C3-Cg)-cycloalky! in whi ch cycloalkyl is unsubstit-uted or 3 substituted independently of one another once, twice or three times by R1, or <) hydrogen atom, where R4 and R5 are identical or differeent are independently of one another a) -(C1-Cg)-alky! or -(C2-C1o)-alkenyl, in which alkyl o r alkenyl is unsubstituted or substitutesd independently of one another once, twice or three timess by R1, bo) -(Cg-C14)-aryl in which aryl is as defined above amd is unsubstituted or substitutead independently of one another once, twice or three times by R1, cc) 4- to 15-membered Het rirg in which Het ring is as- defined above and is unsubstitute«d or substituted independently of one another once, twice o rthree times by R1, dq) -(C3-Cg)-cycloalky! in whiesh cycloalkyl is unsubstituted or substituted independently of one another once, twiece or three times by R1, or e) hydrogen atom, or
R4 and RS form together with the nitrogeen atom to which they aree bonded a ring having 3 to 8 ring atoms selected from the group of propylamine, azetidin e, pyrrolidine, piperidine, azeparaes, azocanes, azepine, cdioxazole, dioxazire, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazo le, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazedline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopipearazine, morpholine, [1,4]oxazep ane, oxazole, piperazine, pyrazine, pyrazolez, pyrazoline, pyrazolidine, pyridaazine, pyridine, pyrimidinez, pyrrole, pyrrolidimone, pyrroline, tetrahydropyridire, thiazole, thiadiazole, thiazolid ine, thiazoline, thiomorpholine, 1 ,2,3-triazine, 1,2,4-triazirme, 1,3,5- triazine, 1,2,3-triazole or 1,2,4-triazole,
® Yis 2)the radical of the formula IV where formula IV is & compound from the group of azetidin-2-one, py~rrolidin-2-one, piperidin-2-one, azepan-2-one and azocan-2-0 ne and is substituted on the nitrogen atom in each casex by R8, where R8 is a) -(Cq-Cg)-alkyl in which alkyl is unsubs tituted or substituted independeritly of one another once, twice or t hree times by R1, b) -(Cs-C14)-aryl in which aryl is as defin ed above and is unsubstitut ed or substituted independently of one another once, twice or three timess by R1, c) 4- to 15-membered Het ring in which Het ring is as defined above and is unsubstituted or substituted independe ntly of one another once, twice or thr-ee times by R1, d) -(Cg3 -Cg)-cycloalkyl in which cycloalkyl is unsubstituted or subsstituted independently of one anothwer once, twice or three times by R21, or e) hydr-ogen atom,
Yis 3)the radical of the formula V, where in case a)
R12 is 1) -(C4-Cg)-alkyl in which alkyl is Linsubstituted or substituted independently of one another orice, twice or three times by=
R1, 2) -(Cp-C3)-alkyl-(C3-Cg)-cycloalkyy! in which cycloalkyl is unsubstituted or substituted indeependently of one another once, twice or three times by R1 3) -(Cg-C3)-alkyl-(Cg-C14)-ary! in vwhich aryl is as defined above and is unsubstituted or su bstituted independently of one another once, twice or three times by R1, or 4) -(Co-C3)-alkyl-Het in which Het i=s as defined above and is unsubstituted or substituted inde pendently of one another once, twice or three times by R1,, and
R13 is 1) -(Cp-C3)-alkyl-(Cg-C14)-aryl in wrhich alkyl and aryl is as defined above and are each unsubstituted or substituted independently of one another once, twice or three times by
R1, or 2) -(Cg-C3)-alkyl-Het, in which alkyl and Het is as defined above and are each unsubstituted or substituted
® inde2pendently of one another once, twice or three times by
R1, or in case b)
R12is 1) hydr-ogen atom, 2) (C1 -Cg)-alky! in which alkyl is ursubstituted or substituted inde=pendently of one another twice or three times by
R1, 3) -(Cow-C3)-alkyl-(Cg-C14)-ary! in which aryl is unsubstituted or subsstituted independently of one ¬her once, twice or threes times by R1, or 4) -(Co -C3)-alkyl-Het in which Het is unsubstituted or subsstituted independently of one &another once, twice or three times by R1, and
R13 is -CH(R8)-RS where R8 and R9 are indepesndently of one another - (Cg-C14)-amyl or Het in which Het and arwyl are each as defined above and are unsubstituted or substituteed independently of one another once, twice or three times by -O—(C4-C4)-alkyl or R1, and
R16, R17, R18 and R19 are identical or different and axe independently of one another 1) hydrogen atom, 2) -(C1-Cg)-all=yl in which alkyl is unsubstitu ted or substituted once or- twice by R1 3) halogen, 4) -OH, 5) -NHo, 6) -(Cp-C3)-alkyl-(Cg-C14)-aryl in which alkyl and aryl is as defined above and aare each unsubstituted or subsstituted independently of one another once, twice or three times by R1, or 7) -(Cp-C3)-alkcyl-Het in which alkyl and Het 3s as defined above and are each unssubstituted or substituted indeependently of one another- once, twice or three times by R1, or
R16 and R17 or R18 and R19 form together with the cambon atom to which they are respectively borded a ring having 3 to 6 ring atoms from the group of cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, or
® Yis 4)the radical of the formula VI, where
R24 and R25 are identical or different and are irmdependently of one anoth «er 1) hydrogen atom, 2) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted cance or twice by R1, 3) -(Co-C3)-alkyl-(Cg-C14)-aryl in whrich alkyl and aryl is as def ined above and are each unsubstituted or substituted independertly of one another once, twice or three ti mes by R1, 4) -(Cp-C3)-alkyl-Het, in which alkyl and Het is as defined above and are each unsubstituted or substitut-ed independently of one amnother once, twice or three times by R1, cor 5) -(Cp-Cg)-alkyl-(C3-Cg)-cycloalkyl, or
R24 and R25 form together with the nitrogen ato m to which they are bonded a ring having 3 to 8 ring atoms from the group of p ropylamine, azetidine, pyrrolidine, piperidine, azepanes, azocanes, azepine, dioxazole, dioxazine, 1,4- diazepane, 1, 2-diazepine, 1,3-diazepine, 1,4-dia=epine, imidazole, imidazo line, imidazolidine, isothiazole, isothiazolidine, isothia=oline, isoxazole, isoxazolime, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4Joxazepane, oxazole, piper-azine, pyrazine, pyrazole, pyrazolime, pyrazolidine, pyridazine2, pyridine, pyrimidine, pyrrole, pyrrolidinone, pyrrolF ne, tetrahydropyridine, thiazole, thiadiazole, th iazolidine, thiazoline, thiomorpholin=e, 1,2 3-triazine, 1,2,4-tria=zine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole,
R26, R27, R28 and R29 are identical or different ~and are independently of cone another 1) Fydrogen atom, 2) —(C1-Cg)-akyl in which alkyl is unsumbstituted or substituted orace or twice by R1, 3) halogen, 4) ~OH, 5) -NH», 6) - (Co-C3)-alkyl-(Cg-C14)-aryl in whic=h alkyl and aryl is as defined above and are each unsubstituted o r substituted independent! y of one another once, twice or three tim es by R1, or
® 7) -(Cp-C3)-alkyl-Het in which alkyl and Het is as defined above and are each unsubstit uted or substituted independerutly of one another once, twice or thre e times by R1, or
R26 and R27 or R28 and R29 form togesther with the carbon atom to wwrhich they are respectiv ely bonded a ring having 3 to 6 ring atoms from the group of ccyclopropyt, cyclobuty=|, cyclopentyl or cyclohexyl,
Zis 1) hydrogen atom, 2) -(C1-Cg)-alkyl, 3) (C3-Cg)-cycloalkyl, 4) (C1-C10)-alkyl-O-C(O)-O -R1, 5) -(CH2)~(Cg-C14)-aryl in which aryl is as defined above and is unsubstituted or substitut ed independently of one anothesr once, twice or three times by R1, and r i s the integer zero, 1, 2 or 3, or 6) -(CH»p)s-Het in which Het is as defined above and is uns=ubstituted or substituted independently of one another once, twice or three times by R1, and s is the integer zero, 1, 2 or 3.
The invemntion further relates to the comapound of the formula la where
Uis hydrogen atom, -CF3, fluorine or -CHg,
X is the radical of the formula Il in which m is the integer 1,
A-lis 1) -(CH2)-, 2) -O-(CH2)p- in which nis the integer zero or 1, or 3) covalent bond,
A22is 1) aminopyridyl in which aminopyridyl is unsubstitutesd or substituted independently of one another once, twice or three times by -(Cq-
Cg)-alkyl, halogen or -CH3, 2) aminothiazolyl in wvhich aminothiazolyl is unsubst ituted or substituted indepe=ndently of one another once, twice or three times by -(C1-Cg)-alkyl, halogen or —CH3, 3) -(C4- Cg)-alkyl-NH2 or 4) -(C3-Cg)-cycloalky/I-NHo,
Yis 1) the radical of the formula lll wshere
_ a) A3 is -(C3-Cg)-cycloalkyi or (C9-Cg)-alkynylene in which c=ycloalkyl of alkynylene is unsubstituted or substituted independently of one another once, twice or three tirmes by -O-R10 or R1,
Ad is —-N(R2)5- in which R2 is as defined below, and the two R2 radicals are defined independently of one another,
AS is absent, o is the integer z ero or 1, and
R10 is hydrogen, -(C1-Cg)-alky! or phenyl, b) A3 is -(C3-Cg)-cycloalkyl in wh ich cycloalkyl is unsubstituted or substituted independently of ore another once, twice or three times by -O-R10 or R1,
A4 is-N(R2)- , and
AS5is a)1) -C(O)-R3, a)2) -C(O)-N(R4)-R5, a)3) -(S02)-R6, or ay) -C(O)-O-R7, o is the integer 1, and p is the integer 1,
Cc) A3 is cyclic amine having 3 to 8 ring atoms in which cyclic zmmine is unsubstituted or substituted independently of one another o nce, twice or three times by R1,
A4 and A5 are as defined under b), where R5 is bonded to the N atom of A3, o is the integer zero, and p is the integer zero or 1, or d) Adis «(CH2)q-(Ce-C14)-ary! in wshich aryl is unsubstituted or substituted independently of one» another once, twice or threee times by R1,
A4 and AS are as defined under b), o is the integer zero or 1, and p is the integer 1, and q is the integer zero, 1, 2 or 3, e) ~A3 is -(CHp)r-Het in which Het is pyrrolidine, benzothiophene= or
FRiperidine, which is unsubstituted or substituted independent! y of one another once, twice or three times by =O or R1, 15 #24 and AS are as defined under b),
® 0 is the integer zero or 1, p is the integer 1 and ris the integer zero, 1, 2 or 3, f) A3 is -(CH2)q-phenyl in which phenyl is unsubstituteed or substituted independently of one another once, twice or three tirmes by R1,
A4 is -O-,
A5 is phenyl, in which phenyl &s unsubstituted or sub stituted independently of one another once, twice or three tirmes by R1, 0 and p are the integer 1 and p is the integer 1 or 2, where= R1 is a) phenyl, where phenyl iss unsubstituted or subsstituted independently of one another once, twice of three tirmes by -(C1-Ca)-alkyl, b) triazolyl or pyridinyl, c) -(C1-Cy)-alkkyl, d) -(C3- Cg)-cycloalkyl, e) -CF3, f) -O-CF3, a) fluorine or h) chlorine, where R2 is a) phenyl in which pheny lis unsubstituted or su bstituted independently of once, twice or —three times by
R1, b) -(Cq- Cg)-alkyl in whic=h alkyl is unsubstituted or substituted independently of one another once, twice or three times by
R1, c) -(C3-Cg)-cycloalkyl in which cycloalkyl! is unssubstituted or substituted independently of one another once, twice or three times by R1, d) -CFg3 or e) hydrogen atom,
® where R3, R6 and R7 are identical or different are independently of one another a) -(C4-Cg)-alkyl in which alkyl! is unsubstituted om substituted independently of one another once, twice or th ree times by
R1, b) -(Cg-C14)-aryl in which aryl is unsubstituted or substituted independently of one another once, twice or th ree times by
R1, c) 4- to 15-membered Het ring in which Het ring i=s unsubstituted or substituted independently of cane another once, twice or three times by R1, d) -(C3-Cg)-cycloalk yl in which cycloalkyl is unsutostituted or substituted independently of one another once , twice or three times by R1 , or e) hydrogen atom, where R4 and R5 are identical or different are independently of one another a) -(C1-Cg)-alkyl or —(C,-Cg)-alkenyl, in which alkyl or alkenyl is unsubstituted or substituted independently of o=ne another once, twice or three times by R1, b) -(Cg-C14)-aryl in which aryl is unsubstituted or substituted independently of one another once, twice or three times by
R1, c) 4- to 15-membered Het ring in which Het ring iss unsubstituted or substituted independently of 0 ne another once, twice or three times by R1, d) -(C3-Cg)-cycloalky! in which cycloalkyl! is unsutostituted or substituted independently of one another once, twice or three times by R1 , or e) hydrogen atom, or
R4 and RS form together with the nitrogen atom to which they are bconded a ring derived from azetidine, pyrrolidine, piperidine, azepanes, azocanes, azepine, dioxazole, dioxazine, 1,4-diazepane, 1, 2-diazepine, 1,3-diazepine, 1 ,4-diazepine, imiciazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, iso thiazoiine, isoxazole, isoxazoline, isoxazolidine, 2~isoxazoline, ketopiperazine, rnorpholine,
® 21 [1,4Joxazepane, oxazole, piperazine, pyrazine, pyrazole, pyraz=aline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidinone, pyrrolinee, tetrahydropyridine, thiazole, thiadiazole, thiazolidine, thiazoline2, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2 4-triazole, 5s Yis 2) the radical of the formula IV selected from the group of azettidin-2-one, pyrrolidin-2-one or piperidin-2-one, where the radical is substit uted on the nitrogen atom in each case by R8, where R8 is a) -(C1-Cg)-alky! in which alkyl is unsubstituted or =substituted independently of one another once, twice or threze times by R1, b) phenyl in which phenyl is unsubstituted or subst ituted independently of one another once, twice or three times by R1 , c) hydrogen atom or d) -(C3-Cg)-cycloalkyl ire which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1,
Yis 3) the radical of the formula V where in the case a)
R12 is 1) -(C1-Cg)-alkyl in which alkyl is unsubstit__ited or substituted independently of one another once, twice or threee times by R1, 2) -(Co-C3)-alkyl-(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or subsstituted independently of ore another once, twice or three times by R1, or 3) -(Cg-Cg)-alkyl -phenyl in which phenyl is unsubstituted or substituted independ ently of one another once, twice or three times by R1, and
R13 is 1) -(Co-C3)-alkyl-pheny! in which alkyl and phenyl are each unsubstituted or substituted independently of one another once, twice or three times by R1, or 2) -(Co-Cg3)-alkyl-pyridyl in which alkyl and pyridyl are each unsubstituted or substituted independently of one another once, twice or three times by R1, or in the case b)
R12 is 1) hydrogen atorm, 2) -(C1-Cg)-alky1 in which alkyl is unsubstit uted or substituted independently of once, twice or three times by R1,
® 3) -(Cg-C3)-alkyl-phenyl in which phenyl is uansubstituted or substituted indepemdently of one another once, t wice or three times by R1, or 4) -(Co-C3)-alkyl-pyridyl in which alkyl and peyridy! are each unsubstituted or substituted independently of on e another once, twice or three time sby R1, and
R13 is -CH(R8)-R9 wherea R8 and R9 are independentlwy of one another phenyl or pyridyl ire which phenyl! or pyridyl are e ach unsubstituted or substituted inde pendently of one another oncee, twice or three times by -O-(C1-C 4)-alkyl or R1, and
R16, R17, R18 and R19 are idertical or different and are independently of one another 1) hydrogen atom, 2) -(C4-C3)-alkyl in which alkyl is unsubstituted or =substituted once or twice by R1, 3) fluorine, 4) -OH, 5) -NH»2 or 6) -(Co-C3)-alkyl-pheenyl, in which alkyl and phenyl are each unsubstituted or s ubstituted independently of ore another once, twice or three times by R1, or
Yis 4) the radical of the formula VI, where
R24 and R25 are identical or dif ferent and are independently «of one another 1) hydrogen atom, 2) -(C4-Cg)-alkyl in wvhich alkyl! is unsubstituted or substituted once or twice by R1, 3) -(Cp-Ca)-alkyl-phenyl in which alkyl and phenyl are each unsubstituted or substituted independently of ore another once, twice or three times by R1, or 4) -(Co-C3)-alkyl-(C3—Cs)-cycloalkyl, or
R26, R27, R28 and R29 are ide ntical or different and are independently of one another 1) hydrogen atom,
® 2) -(C1- Ca)-alk<yl in which alkyl is unsubsstituted or substituted once or twice by R1, 3) fluorine, 4) -OH, 5) -NH2 or 6) ~(Cp-C3)-alk-yl-phenyl in which alkyl an d phenyl are each unsubstituted or substituted independently of one another once, twice or threee times by R1, and
Z is hydrogen atom or (C1-C4)-alw/l.
The invention further relates to thee compound of the formulaa la, where
Uis hydrogen atom,
Xis the radical of the formula | 3 in which m is the integer 1,
A1lis -(CH2)-,
A2is aminopyridyl in whicch aminopyridyl is unsubstituted or substituted independently of orme another once, twice or three times by halogen or -CHg,
Yis 1) the radical of the formula lll where a) A3 is -(C3-Cg)-cycloalkyl in which cycloalkyl iss unsubstituted or substituted independently of one another once, twice or three tirmes by R1, and A4 and AS are absent, b) A3 is -(C3-Cg)-alkyrylene in which alkynylene= is unsubstituted or substituted independently ef one another once, twicez or three times by R1, and
A4 and AS are absent,
Cc) A3 is cyclic amine Maving 3 to 8 ring atoms in which cyclic amine is unsubstituted or substitute-d independently of one an other once, twice or three times by R1, and A4 and Aa5 are absent, d) A3 is -(CH2)g-phen-ylin which phenyl is unsulostituted or substituted independently of one another once, twice or three tires by R1,
Ad is -N(R2)- in which R2 i s as defined below
Asis a)l) -C(O)-R3, a)2) -C(O)-N(R4)—R5, a)3) -(S0O2)-R6 or
Claims (10)
1. A compound of the formula X So u = z—0 and/or all stereoisomeric forrns of the compound of the formula | and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, where Uis 1) hydrogen atom , 2) -(C4-Cg)-alkyl, 3) -(C3-Cg)-cycloalkyl, 4) fluorine, 5) -O-CF3 or 6) -CF3, Xis the radical of the form ula ll -(A1)m-A2 (in in which m is the integer zero or 1, Atlis 1) -(CH)n- in which n istheinteger 1,2 or 3, or 2) -O-(CH2)n- in wvhich n is the integer zero, 1, 2 or 3, A2is 1) 4- to 15-memb ered Het ring in which Het ring ccomprises at least one N atom and is substituted by an amino group and may additionally be substituted independently of onee another once, twice or three times by a -(C1-C3)-alkyl, halogen, -C F3 or -O-CF3, 2) -(C1-Cg)-alkyl-INH» or 3) -(C3-Cg)-cycloalkyl-NHo, Y is 1) the radical of the form ula Ill A3-(Ad)o-(Ad)p (nn where a) A3 is -(C3-Cg)- cycloalkyl or -(C2-Cg)-alkynylerae, in which cycloalkyl or alkynylene is unsubstituted or substituted incdependently of one
® another once, twice or three times by -O-R10 or R11, Ad is -N(R2)2- in which R2 is as defined below, ard the two R2 radicals are defined independently of one another, Ab is absent, ois the in teger zero or 1, and R10 is a hydrogen atom , -(C4-Cg)-alky! or -(Cg-C1 4)-aryl,
b) A3 is -(C3-Cg)-cycloalkyl in which cycloalkyl is uns ubstituted or substituted independent ly of one another once, twi ce or three times by -O-R10 or R1,
A4 is-N(R2)-, and AS5is a)l) -C(O)-R3, a)2) -C(O)-N(RR4)-RS5, a)3d) -(SO2)-R6, or a4) -C(0O)-O-Ri7, ois the integer 1, and p is the integer 1,
c) AJ is cyclic amine havin g 3 to 8 ring atoms in which cyclic amine is unsubstituted or substitLated independently of one eanother once, twice or three times by Rt,
A4 and AS are as define=d under b),
where AS is bonded to tke N atom of A3, o is the integer zero, and p is the integer zero or 1 , or d) A3 is -(CH2)q-(Ce-C14)—aryl in which aryl is unsubsstituted or substituted independentBy of one another once, twicze or three times by R1,
A4 and A5 are as define d under b), o is the integer zero or 1 , and p is the integer 1, and q is the integer zero, 1, 2 or 3,
e) A3 is -(CH2)-Het in which Het is a 4- to 15-membesred Het ring, and Het ring is unsubstituted or substituted indeperdently of one another once, twice or tharee times by =O or R1,
A4 and AS are as define«d under b), ois the integer zero or 1 , p is the integer 1 and
® ri sthe integer zero, 1, 2 or 3,
f) AJ is -(CH2)q-(Ce-C14)-aryl, in which aryl is unsubstituted or substituted independently of one anaether once, twice or three tines by R1,
A4 is -O-, AS is -(Cg-C14)-aryl, in which aryl is munsubstituted or substituted independently of one another once, twice or three times by R1, o and p are the integer 1 and q i s the integer zero, 1, 2 or 3, a) -GH(-(Ce-C14)-aryl)-(Ce-C14)-aryl, where R1 is a) -(Ce-C14)-aryl, where aryl is u nsubstituted or substituted independently of one another nce, twice or three times b=y -(C1-Ce)-alkyl, -(Cp-C4)-alkyl-CC3-Cg)-cycloalkyl, -CF3, =O, -O-CF 3 or halogen, b) 4- to 15-membered Het ring, c) -(C1-Cg)-alkyl, d) -(Cp-Cq)-alkyl-(C3-Cg)-cycloal kyl, e) -CF3, f) -O-CFz or a) halogen, where R2 is a) ~(Cg-C14)-aryl in which aryl is wnsubstituted or substituted independently of one another once, twice or three times bwy R1, b) -(C1-Cg)-alky! in which alkyl is unsubstituted or substitutecd independently of one another osnce, twice or three times byy R1, Cc) -(C3-Cg)-cycloalkyl in which cyesloalkyl is unsubstituted or substituted independently of on e another once, twice or three times by R1, d) -CF3 or e) hydrogen atom,
® © j006 07088 where R3, R6 and R7 are id entical or different is indeperdently of one another a) -(C1-Cg)-alky! in which alkyl is unsubstitute=d or substituted independently of one another once, twice cor three times by
R1,
b) -(Cg-C14)-aryl in which aryl is unsubstitute=d or substituted independently of one another once, twice cor three times by R1,
c) 4- to 15-membered Het ring in which Het ring is unsubstituted or substituted independently= of one another once, twice or three times by R1,
d) -(C3-Cg)-cycloalky! in which cycloalkyl is u nsubstituted or substituted independently of one another once, twice or three times by R1, or e) hydrogen atom, where R4 and R5 are identical or different is independermtly of one another a) -(C1-Cg)-alkyl or -(C,-Cqo)-alkenyl, in which alkyl or alkenyl is unsubstituted or substituted independently of one another once, twice or three times by R1,
b) -(Cg-C14)-aryl in which aryl is unsubstitute=d or substituted independently of one another once, twice or three times by R1,
c) 4- to 15-membered Het ring in which Het riling is unsubstituted or substituted independently of one another once, twice or three times by R1,
d) -(C3-Cg)-cyclo alkyl in which cycloalkyl is umnsubstituted or substituted ind ependently of one another osnce, twice or three times by R1, or e) hydrogen atom, or
R4 and RS form together with the nitrogen atom to whicha they are bonded a ring having 3 to 8 ring atoms which may, in addition to —the nitrogen atom, also comprise one to two additional heteroatoms from the= series oxygen, sulfur or nitrogen,
Y is 2) the radical of the formula IV,
® 74
0] ah , (IV) L Cys where R8 is a) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted independently of one another nce, twice or three times by R1,
b) -(Cg-C14)-aryl in which aryl is unsubstituted or substituted independently of one another nce, twice or three times by R1,
Cc) 4- to 15-membered Het ring in which Het ring is a0 unsubstituted or substituted inedependently of one another once, twice or three times by R1,
d) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of ome another once, twice or three times by R1, or as e) hydrogen atom, Yis 3) the radical of the formula V 0) R16 R17) R12 (flo R13 2 R18 R19 where in cas e a)
R12is 1) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted independen tly of one another once, twice or three times by R1,
2) -(Cg-C3)-alkyl-(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one arother once, twice or three times by R1,
3) -(Co-Cg)-alkyl-(Cg-C14)-aryl in which aryl is unsubstituted or substit uted independently of one another once, twice or t-hree times by R1, or
® 4) -(Cp-C3)-alkyl-Het in whi ch Het is urisubstituted or substituted indeependently of one armother once, twice or three tim es by R1, and R13 is 1) -(Cp-C3z)-alkyl-(Cg-C14)—aryl in which alkyl and aryl are each unsubstituted or s ubstituted independently of one another orice, twice or three tiles by R1, or 2) -(Co-Cg)-alkyl-Het in whi ch alkyl and Het are each unsubstituted or substitute=d independently of ore another once, twice or threes times by R1, where in case b) R12is 1) hydrogen atom, 2) -(C1-Cg)-alkyl in which a-lky! is unsubstituted or substituted independently of ones another once, twice or three times by R1, 3) ~(Cp-C3)-alkyl-(Cg-C14)- aryl in which aryl is ure substituted or substituted indespendently of one ars other once, twice or three timees by R1, or 4) -(Cp-C3)-alkyl-Het in whiach Het is une substituted or substituted independently of one an other once, twice or three timees by R1, and R13 is -C H(R8)-R9 where R8 and R9 a_re independently of on e another -(Cg-C14)-aryl or H et in which Het and aryl are each unsubstituted or stibstituted independently of one another ormce, twice or three times by -O-(C1-C4)-alkyl or R1 , and R16, R17, R18 and R19 are id entical or different and are incdependently of one another 1) hydrogen atom, 2) -(C4-Cg)-alkyl, im which alkyl is unsubstituted cr substituted once or twice by R1, 3) halogen, 4) -OH, 5) -NH»,
® 6) -(Cg-Ca)-alkyl-(Cg-C14)-aryl in which alkyl and aryl are each unsubstituted or sub stituted independently of one another once, twice or three times by R1, or 7) -(Cg-Cga)-alkyl-Het ira which alkyl and Het are each unsubstituted or substituted independently of one another once, twice or three times by R1, or R16 and R17 or R18 and R19 form together with the carbon atom to which they are respectively bonded a ring having 3 to 6 ring atoms, or Y~is 4) the radical of the formula VI,
R27 Ni Red — SNC (VI) (Roz "R25 i eo wrhere R24 and R25 are identical or different and are independently of one another 1) hydrogen atom, 2) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted once or twice by R1,
3) -(Cp-C3)-alkyl-(Cg-C 14)-aryl in which alkyl and aryl are each unsubstituted or substituted independently of one another once, twice or three times by R1,
4) -(Cp-Ca)-alkyl-Het in which alkyl and Het are eache unsubstituted or substituted independently of one another once, tw ice or three times by R1, or
5) -(Cp-C3)-alkyl-(C3-Cg)-cycloalkyl, or R 24 and R25 form together with the nitrogen atom to which they~ are bonded a rirg having 3 to 8 ring atoms which may, in addition to the nitrog en atom, also comprise one to two additional hetearoatoms from the series oxygen, sulfur or ni-trogen,
R226, R27, R28 and R29 are identical or different and are indepe ndently of one arother 1) hydrogen atom, 2) -(C4-Cg)-alkyl in whic=h alkyl is unsubstituted or sukostituted once or 40 twice by R1,
® 3) halog en, 4) -OH, 5) -NHo 6) -(Cp-CC3)-alkyl-(Cg-Cq4)-aryl in which alkyl and ary! are each unsubstituted or substituted indepemdently of one another once, twice or three times by R1, or 7) -(Co-CC3)-alkyl-Het in which alkyl an d Het are each unsubstituted or substututed independently of one armother once, twice or three t imes by R1 ,or R26 and R27 or R2 8 and R29 form together with the carbon atom to which they are respectively bornded a ring having 3 to 6 ring atoms, Zis 1) hydro gen atom, 2) -(C1-CCp)-alkyl, 3) -(C1—Cpg)-alkyl-OH, 4) -(Co-C4)-alkyl-(C3-Cg)-cycloalkyl, 5) -(C1-C)-alkyl-O-C(O)-O-R1, 6) -(CH2=»)~(Cg-C44)-aryl in which aryl is unsubstituted or substituted independently of one another once, twice Or three times by R1, and r &s the integer zero, 1,2or 3, or 7) -(CHz=)s-Het in which Het is unsubstituted or substituted independent! y of one another once, twice or three times by R1, and s is the integer zero, 1, 2 or 3.
2. A compound of the formula la, as claimed in claim 1, where X SH N=Y (a) z—0 UNF Uis 1) hydrocgen atom, 2) -(Cq-Cg)-alkyl, 3) -(C3-C¢)-cycloalkyl, 4) fluorin e, 5) -O-CF gor
® 6) -CF3,
Xis the radical of the formula ll in which m is the integer zero or 1,
Alis 1) -(CH2)n- in which nis the integer 1, 2 or 3, or
2) -O-(CH2)p- in which n is the integer zero, 1, 2 or 3,
A2is 1) 4- to 15-membered Het ring in which Het ring is selecteed from the group of acridinyl, azepinyl, azetidiryl, aziridinyl, benzimidazaalinyl, bernzimidazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinoli=inyl, qui noxalinyl, quinuclidinyl, chromaryl, chromenyl, cinnolinyl, deca-
hydiroquinolinyl, imidazolidinyl, imid azolinyl, imidazolyl, 1H-incdazolyl, ind olinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isoctkromanyl, iso indazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazeolyl), iso thiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxaz=olidinyl, 2- iso xazolinyl, morpholinyl, naphthyri dinyl, octahydroisoquinolirayl,
oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadia zolyl, 1,3s,4-oxadiazoly!, oxazolidinyl, oxa=olyl, pyrimidinyl, phenanttridinyl, phesnanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, p henoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purynyl, pyran—yl, pyrazinyl, pyr-oazolidinyl, pyrazolinyl, pyrazoly’|, pyridazinyl, pryidooxazoRyl,
pyr-idoimidazolyl, pyridothiazolyl, py ridothiophenyl, pyridinyl, peyridyl, pyr-imidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyi, tetr—ahydroisoquinolinyl, tetrahydroq uinolinyl, tetrahydropyridinayl, 6H-1,2,5- thiaadazinyl, 1,2,3-thiadiazolyl, 1,2,4 -thiadiazolyl, 1,2,5-thiadia=olyl, 1,3,4- thizadiazolyl, thianthrenyl, thiazolyl, £hienothiazolyl, thienooxaz oly,
thieanoimidazolyl, thiomorpholinyl, triazinyi, 1,2,3-triazolyl, 1,2, 4-triazolyl, 1,2 ,5-triazolyl, 1,3,4-triazolyl and xanthenyl and in which the Het ring is sulostituted by an amino group and may additionally be substi tuted ind ependently of one another once, twice or three times by a -(C4-C3)- alk=yl, halogen, -CF3 or -O-CF3,
2) -(C1-Cg)-alkyl-NH»o or 3) -(C3-Cg)-cycloalkyl-NHo,
Yis 1)t he radical of the formula ill where a) A3 is -(C3-Cg)-cycloalkyl or —(C2-Cg)-alkynylene in which cycloalkyl or alkylnylene is unsubstitutexd or substituted independently of one
® a nother once, twice or three timess by -O-R10 or R1, M4 is-N(R2)2- in which R2 is as defined below, and the two R2 radicals are defined independerw tly of one another, M5 is absent and o is the integer zero or 1, and R10 is hydrogen atom, -(C1-Cg) -alkyl or phenyl,
b) M3 is -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituteed or s=ubstituted independently of one another once, twice or three times »y-0-R10 or R1,
Ad is-N(R2)-, and M5is a)l) -C(O)-R3, a)2) -C(O)-N(R4)-R5, a)3) -(SO92)-R6, or a) -C(O)-O-R7, © is the integer 1, and [> is the integer 1,
c) Al is cyclic amine from the group of propylamine, azetidinee, pyrrolidine, piperidine, azepaness or azocanes, in which cyclic amine iss unsubstituted or substituted independently of one anothear once, twwice or three times by R1,
A\4 and AS are as defined under b), v-vhere AS is bonded to the N atom of A3, © is the integer zero, and pP is the integer zero or 1, or d) Ais -(CH2)q-(Ce-C14)-aryl in which aryl is selected from the group Of phenyl, naphthyl, anthry! or fleuorenyl and is unsubstitute-d or Ssubstituted independently of one another once, twice or three times by R1, Ad and A5 are as defined under b) oO is the integer zero or 1, and is the integer 1, and is the integer zero, 1, 2 or 3,
e) AJ is -(CH2)-Het in which Het i=s as defined above and is unsubstituted or substituted independently of one another once, twice or three times by =O or R11,
A\4 and A5 are as defined under b),
® 0 iss the integer zero or 1, p iss the integer 1 and r iss the integer zero, 1, 2 or 3, f) A3is -(CH2)q-(Ce-C14)-aryl in wh ich is aryl is unsubstituted or sun bstituted independently of one &another once, twice or tharee times by~ R1, A4- is -O-, ASe is -(Cg-C14)-aryl in which aryl i s unsubstituted or substituted incdependently of one another once, twice or three times bw R1, o and p are the integer 1 and q i-s the integer zero, 1, 2 or 3, a9) -CH(phenyl)-phenyl, where R1 is a) -(Cg-C14)-aryl in which aryll is as defined above ancl where anwyl is unsubstituted or is substitut ed independently of one- another on ce, twice or three times by -(C1—Cg)-alkyl, -(Co-C4)-alky |-(C3-Cg)- cyecloalkyl, -CF3, =O, -O-CF3 or halogen b) 4- to 15-membered Het ring in which Het is as defired ab ove, c) -(C1-Cg)-alkyl, d) -(C3-Cg)-cycloalkyi, e) -CF3, f) -O-CF3 or a) halogen, where R22 is a) -(Ce-C14)-aryl in which aryl is as defined above and is unsubstituted or substituted independently of one another once, twice or three times toy R1, b) -(C1-Cg)-alkyl in which alkyl is unsubstituted or submstituted independently of one anoth er once, twice or three t imes by R1, Cc) -(C3-Cg)-cycloalkyl in whick cycloalkyl is unsubstituted or substituted independently cof one another once, twice or on gr2006/ 0760 ® three times by R1, d) -CF3 or e) hydrogen atom , where R3, R6 and R7 are ide=ntical or different is independently of one another a) -(C1-Cg)-alkyl i n which alkyl is unsubstituted or substituted independently of one another once, twice or &hree times by R1,
b) -(Cg-C14)-aryl in which aryl is as defined above and is unsubstituted oer substituted independently of one another once, twice or t hree times by R1,
c) 4- to 15-membe=red Het ring in which Het ringm is as defined above and is ursubstituted or substituted independently of one another one, twice or three times by R1 ,
d) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted indexpendently of one another onc e, twice or three times by R1, or e) hydrogen atom,
where R4 and R5 are identical or different is independently of one another a) -(C1-Cg)-alkyl or -(C,-Cqo)-alkenyl, in which allikyl or alkenyl is unsubstituted or substituted independently of one another once, twice or three times by R1,
b) -(Cg-C14)-aryl im which ary! is as defined abo=ve and is unsubstituted or= substituted independently of one another once, twice or three times by R1,
c) 4- to 15-membesred Het ring in which Het ring is as defined above and is un substituted or substituted independently of one another once, twice or three times by R1,
d) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsumbstituted or substituted indepoendently of one another once, twice or three times by R1, or e) hydrogen atom, or
R4 and RS form together with the nitrogen atom to which thesy are bonded a ring having 3 to 8 ring atoms selected from the group of pr-opylamine, azetidine, pyrrolidine, piperidin e, azepanes, azocanes, azepiine, dioxazole,
PS 82 dioxazine, 1,4-diazepan ee, 1,2-diazepine, 1,3-diazepin e, 1,4-diazepine, imidazole, imidazoline, i midazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-i-soxazoline, ketopiperazine, morphol ine, [1,4]Joxazepane, oxazole, piperazine, pyrazine,
pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridines, pyrimidine, pyrrole, pyrrolidinone, pyrroline, tetrahydropyridine, thiazole, thiadiazole, thiazolidine, thiazoline, t hiomorpholine, 1,2 3-triazine, 1,2,4-triazine, 1,3,5- triazine, 1,2,3-triazole or 1,2,4-triazole,
Y is 2) the radical of the formula IV where formula IV is a co mpound from the group of azetidin-2-one, pyrrolidin-2-one, piperidin-2-cne, azepan-2-one and azocan-2-one and iss substituted on the nitrogen eatom in each case by R8, where R8 is a) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted independexntly of one another once, twicze or three times by R1,
b) -(Ce-C14)—aryl in which aryl is as definecd above and is unsubstituted or substituted independermtly of one another once, twice or three times by R1,
c) 4- to 15-m embered Het ring in which He=t ring is as defined above and is unsubstituted or substitute=d independently of one another once, twice or three times toy R1,
d) -(C3-Cg)-cycloalky! in which cycloalkyl is unsubstituted or substituted independently of one anothe r once, twice or three times by R1, or e) hydrogen atom,
Yis 3) the radical of the formula V, where in case a) R12is 1) -(C1-Cg)-alkyl in which alkyl is unsubstit-uted or substituted independently of one another once, twicse or three times by
R1,
2) -(Cg-Cg)-a lkyl-(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstitut ed or substituted independently of one another once, twice= or three times by R1,
® 3) -(Cp -Ca)-alkyl-(Cg-C14)-aryl in which aryl is as defined abowe and is unsubstituted or substituted independently of one another once, twice or three times by R1, or 4) -(Cp -C3)-alkyl-Het in which Het is a s defined above and is unsubstituted or substituted indepemndently of one another once, twice or three times by R1, ard
R13 is 1) -(Cp -C3)-alkyl-(Cg-C14)-aryl in which alkyl and aryl is as defirmed above and are each unsubstituted or substituted inde pendently of one another once, twice or three times by”
R1, or
2) -(Cp -Cg)-alkyl-Het, in which alkyl arnd Het are as defined abowe and are each unsubstituted Or substituted inde pendently of one another once, twice or three times by= R1, or in case b) R12 is 1) hydrogen atom,
2) -(Cq -Cg)-alkyl in which alkyl is unsubstituted or substituted inde pendently of one another once, twice or three times by” R1,
3) -(Cp -C3)-alkyl-(Cg-C14)-aryl in which aryl is unsubstituted or subsstituted independently of one armother once, twice or threex times by R1, or
4) -(Cp -C3)-alkyl-Het in which Het is u nsubstituted or subsstituted independently of one an other once, twice or three times by R1, and
R13 is -CH(R8)-RS where R8 and R9 are indepermdently of one another - (Ce-C14)-aryl or Het in which Het and aryl are each as defined above and are unsubstituted or substituted independently of one another once, twice or three times by -O-(C1-C4)-alkyl or R1, and
R16, R17, R18 and R19 are identical or different and are= independently of one another
1) hydrogen atom, 2) -(C1-Cg)-alkyl in which alkyl is unsubstitute=d or substituted once cor twice by R1 ,
® 3) halogen,
4) -OH,
5) -NH>,
6) -(€Cg-Cg)-alkyl-(Cg-C14)-aryl in which alkyl and aryl is as definead above and are each unsubstituted or substituted independently~ of ore another once, twice or three times by R1, or
7) -(<Cp-C3)-alkyl-Het in which alkyl and Het is as defined above a nd ar-e each unsubstituted or substituted independently of one another orice, twice or three times by R1, or
R16 and R17 or R18 and R19 form together with tthe carbon atom to which tiey are respectively bonded a ring having 3 to 6 ring atoms from the groupo of cyclopropyl, cyclobutyl, cyclopentyl or cyclobexyl, or Yis 4) the radical of the formula VI, where R24 and R25 are identical or different and are inde=pendently of one another
1) hwdrogen atom,
2) -(<€C1-Cg)-alkyl in which alky! is unsubmstituted or substituted once or twice by R1,
3) -(€Cp-Ca)-alkyl-(Cg-C14)-aryl in which alkyl and aryl is as defined aboove and are each unsubstituted or substituted independently of ore another once, twice or three times by R1,
4) -(€Cg-C3)-alkyl-Het, in which alkyl and Het is as defined above and ar-e each unsubstituted or substituted independently of one anther orice, twice or three times by R1, or
5) -(€C-C3)-alkyl-(C3-Cg)-cycloalkyl, or
R24 and R25 fosrm together with the nitrogen atom to which they are bonded a ring having 3 to 8 ring atoms from the group of progoylamine, azetidine, pyrrolidine, pipe=ridine, azepanes, azocanes, azepire, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-di azepine, imidazole, imidazoline, imi«azolidine, isothiazole, isothiazolidime, isothiazoline, isoxazole,
isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole, piperazine, pyrazine, pyrazole, pyrazoline, pyrazoliciine, pyridazine, pyricline, pyrimidine, pyrrole, pyrrolidino ne, pyrroline, tetrahydropyridime, thiazole, thiadiazole, thiazolidines, thiazoline, thiomorpholire, 1,2,3-triazine, 1 ,2,4-triazine, 1,3,5-triazine, 1,2,3-trizazole or 1,2 4-triazole,
® 85
R26. R27, R28 and R29 are identical or different and are indepe-ndently of one anot her 1) hydrogen atom, 2) -(Cq-Cg)-alkyl in whic h alkyl is unsubstituted or su bstituted once or twice by R1, 3) halogen, 4) -OH, 5) -NHo, 6) -(Cg-Cg3)-alkyl-(Cg-Cq 4)-aryl in which alkyl and aryl is as defined above and are each wansubstituted or substituted independently of one another once, twi ce or three times by R1, or 7) -(Cp-Cg)-alkyl-Het in which alkyl and Het is as def’ined above and are each unsubstitute=d or substituted independently of one another once, twice or three ti mes by R1, or R26 and R27 or R28 and R29 form together with the carbon ato.m to which they are respectively bonded a ring havirg 3 to 6 ring atoms from the= group of cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, Zis 1) hydrogen atom, 2) -(Cq-Cg)-alkyt, 3) (C3-Cg)-cycloalkyl, 4) (C1-C1)-alkyl-O-C(3)-0O-R1, 5) -(CH2)~(Cg-C14)-ary 1in which aryl is as defined above and is unsubstituted or substituted Endependentiy of one anothemr once, twice or three times by R1, and ris the integer zero, 1, 2 or 3, or 6) -(CHg)g-Het in which Het is as defined above and is unsubstituted or substituted independently of one another once, twice cr three times by R1, and s is the integer zero, 1, 2 or 3.
3. A co mpound of the formula la as claimed in claims 1 or 2, where Uis hydrogen atom, -CF3, fluorine or ~CH3, X is the radical of the formula | in which mis the integer 1, Allis 1) -(CHg)-, 2) -O-(CHaz)n- in which ra is the integer zero or 1, or
® 86 3) cavalent bond, A2is 1) aminopyridyl in which aminopyridyl is unsubstituted or substituted independently of one another once, twice or three times toy -(C4-Cg)-alkyl, halogen or —-CHg3,
S 2) aminothiazolyl in which aminothiazoly! is unsubstituted or substituted independently of one another once, twice or three times by -(C4-Cg3)-alky!, halogen or ~CH3,
3) -(C4- Cg3)-alkyl-NH»o or 4) -(C3-Cg)-cycloalkyl-NH>, Y”is 1) the radical of the formula lll where a) A3 is -(C3-Cg)-cycloalkyl or (C2-Cg)-alkynylene in which cycloalkyl or alkynylene is unsubstituted or substituted independent ly of one another once, twice or three times by R1, Ad is -N(R2)2- in which R2 is as defined below, and the two R2 radicals are defined independently of one another, AS is absent and o is the integer zero or 1, b) A3 is -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstitu ted or substituted independently of one another once, twice or three times by R1, Ad is—N(R2)- , and ASis a)1) -C(O)-R3, a)2) -C(O)-N(R4)-R5, a)3) -(S02)-R6 or a4) -C(O)-O-R7, o is the integer 1, and p is the integer 1, c) A3 is cyclic amine having 3 to 8 ring atoms in which cycliec amine is unsubstituted or substituted independently of one anothe r once, twice or three times by R1, A4 and AS5 are as defined under b), where A5 is bonded to the N atom of A3, o is the integer zero, and p is the integer zero or 1, or
® d) A3 is -(CH2)q-(Cp-C14)-aryl in which aryl is unsubstituted or substituted independently «f one another once, twicee or three times by R1, A4 and A5 are as defined winder b), o is the integer zero or 1, and p is the integer 1, and q is the integer zero, 1, 2 or 3, e) A3 is -(CH»9)-Het in which Het is pyrrolidine, benzot hiophene or piperidine, which is unsubsstituted or substituted independently of one another once, twice or three times by =O or R1 A4 and A5 are as defined under b), o is the integer zero or 1, p is the integer 1 and ris the integer zero, 1, 2 ox 3, f) A3 is -(CH2)q-phenyl in which phenyl is unsubstituted or substituted independently of one another once, twice or three tirmes by R1, Ad is -O-, AS is phenyl, in which pheryl is unsubstituted or sutostituted independently of one another once, twice or three tirmes by R1, o and p are the integer 1 a nd q is the integer 1 or 2, where R1 is a) phenyl, where phen yl is unsubstituted or subsstituted independently of one another once, twice of three tirnes by -(C1-C4)-alkyl, b) triazolyl or pyridinyl, c) -(Cq-Cy)-alkyl, d) -(C3- Cg)-cycloalkyl , e) -CF3, f) -O-CF3, a) fluorine or h) chlorine, where R2 is a) phenyl in which phe nyl is unsubstituted or subostituted
® independently of on e another once, twice or three times by R1,
b) -(C1- Cg)-alkyl in which alkyl is unsubstituted or stubstituted independently of on € another once, twice or three times by R1,
Cc) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1,
d) -CF3 or e) hydrogen atom, where R3, R6 and R7 are identica | or different are independent!wy of one another a) -(C1-Cg)-alkyl in which alkyl is unsubstituted or su bstituted independently of one another once, twice or three times by
R1,
b) -(Cg-C14)-aryl in whrich aryl is unsubstituted or sulostituted independently of one another once, twice or three times by R1,
c) 4- to 15-membered Het ring in which Het ring is unsubstituted or sub stituted independently of one another once, twice or three times by R1,
d) -(C3-Cg)-cycloalkyl i n which cycloalkyl is unsubstit uted or substituted independently of one another once, twi ce or three times by R1, or e) hydrogen atom, where R4 and RS are identical or different are independently of one another a) -(C1-Cg)-alkyl or (C, -Cg)-alkenyl, in which alkyl or =alkenyl is unsubstituted or substituted independently of one another once, twice or three gimes by R1,
b) -(Cg-C14)-aryl in whi ch aryl is unsubstituted or submstituted independently of ones another once, twice or three times by R1,
Cc) 4- to 15-membered Het ring in which Het ring is unsubstituted or substituted independently of >
° once, twice or three times by R1,
d) -(C3-Cg)-cycloalkyl i nm which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, om e) hydrogen atom, or R4 and R5 form together with the mitrogen atom to which they are bonded a ring derived from azetidine, pyrrolidine, piperidine, azepames, azocanes, azepine, dioxazole, dioxazine, 1,4~ diazepane, 1,2-diazepinez, 1,3- dliazepine, 1,4-diazepine, imidazole, imidazoline, imidazoiidlline, isothiazole, issothiazolidine, isothiazoline, isoxa==zole, isoxazoline, isoxazolidine, 2- issoxazoline, ketopiperazine, morph oline, [1,4Joxazepane, oxazole, piperazine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyr-idazine, pyridine, pyrimidine, pyrrole, pyrrol@dinone, pyrroline, tetrah=ydropyridine, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine=, 1,2 3-triazine, 1 ,2,4-triazine, 1,3,5-triazine, 1,2,3-&riazole or 1,2,4-triazole, Yis 2 )the radical of the formula IV selected from the group of aazetidin-2-one, p yrrolidin-2-one or piperidin-2-one, where the radical is sub-stituted on the nitrogen atom in each case by R8, where R8 is a) -(C4-Cg)-alkyl in which alkyl is unsubstituted or subsstituted independently of one anothear once, twice or three tirmes by R1,
b) phenyl in which phenyl is un substituted or substituted independently of one another once, twice cor three times by R1,
c) hydrogen atom or d) -(C3-Cg)-cycioalkyl in which cycloalkyl is unsubstitute=d or substituted independently of one another once, twice2 or three times by R1,
Yis 3) the radical of the formula V where in the case a)
R12 is 1) -(C4-Cg)-alkyl in whic=h alkyl is unsubstituted oor substituted independently of one anothe=r once, twice or three tines by R1,
2) -(Cp-Cg)-alkyl-(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one aneother once, twice or three times by R1, cer 3) -(Cp-C3)-alkyl-phenyl in which phenyl is unsubstituted or substituted independently of one another once, twice or three times by R1, and
° 0 pn06/ ©7668 R13 is 1) -(Cp-C3)-alkkyl-phenyl in which alkyl and phen=yl are each unsubstituted or substituted independently of one armother once, twice or three timers by R1, or 2) -(Co-C3)-alkyl-pyridyl in which alkyl and pyridwy! are each unsubstituted or substituted independently of one an other once, twice or three times by R1, or in the case b) ‘ R12is 1) hydrogen atom, 2) -(C1-Cg)-alkyl in which alkyl is unsubstituted or substituted independently of o ne another once, twice or three tirmes by R1, 3) -(Cp-C3)-alkyl-phenyl in which phenyl is unsubstituted or substituted independently of one another once, twice or three times by R1, or 4) -(Cg-C3)-alkyl-pyridy! in which alkyl and pyrid~y! are each unsubstituted or substituted independently of one an other once, twice or three time s by R1, and R13 is -CH(R8)-R9 wherez R8 and R9 are independently of cone another phenyl or pyridyl in which phenyl or pyridyl are each unsubstituted or substituted inde pendently of one another once, twice or three times by -O-(C1-C4)-alky! or R1, and R16, R17, R18 and R19 are identical or different and are independently of one another 1) hydrogen atom, 2) -(C4-C3)-alkyl in wrhich alkyl is unsubstituted or subs tituted once or twice by R1, 3) fluorine, 4) -OH, 5) -NHo or 6) -(Cp-C3)-alkyl-phe nyl, in which alkyl and phenyl are «each unsubstituted or substituted independently of one an other once, twice or three time sby R1, or Y is 4)the radical of the formula VI, where R24 and R25 are identical or diff erent and are independently of on e another 1) hydrogen atom,
® 2) -(C1-Cg)-alkyl in whiech alkyl is unsubstituted or substituted once or twice by R1, 3) -(Cg-Cga)-alkyl-pheny~l in which alkyl and phenyl! are each unsubstituted or substituted independently of orx e another once, twice or three times boy R1, or 4) -(Cp-C3)-alkyl-(C3-Ces)-cycloalkyl, or R2 6, R27, R28 and R29 are identical or different and are inde goendently of one another 1) hydrogen atom, 2) -(C1- C3)-alky! in which alkyl is unsubstituted or substituted once or twice by R1, 3) fluorine, 4) -OH, 5) -NHo or 6) -(Co-C3)-alkyl-pheny~lin which alkyl and phenyl =are each unsubstituted or subsstituted independently of on e another once, twice or three times boy R1, and Z iss hydrogen atom or (C1-Cg4)-alkyvl.
4. A compound of the formula la as claimed in claims 1 or 2, where Uiss hydrogen atom, X is the radical of the formula ll in which m i s the integer 1, A1 is -(CHbg)-, A2 is aminopyridyl in which aminopyridyl is unsubstituted or substituted independently of one anothear once, twice or three times by halogen or -CH3, Y is 1) the radical of the formula [ll where a) A3 is -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubsti—tuted or substituted indezpendently of one another once, twice or three times by R1 , and A4 and A5 are absent, b) A3 is -(C2-C4)-alkynylene in which alkynylene is unsubstituted or subwstituted independently of one arother once, twice or three times by R1, and A4 and AS are absent,
® 92 c) A3 is cyclic amine having 3 to 8 rimg atoms in which cyclic amine is unsub stituted or substituted independent! y of one another once, twice or t hree times by R1, and A4 and AS are absent, d) A3 is -(CH2)q-pheny! in which phe ny! is unsubstituted or substitute d indepe=ndently of one another once, twice or three times by R1, A4 is —N(R2)- in which R2 is as defined below AS5is a)1) -C(O)-R3, a)2) -C(O)-N(R4)-R5, a)3) -(SO2)-R6 or a)y4) -C(O)-O-R7, ois thes integer 1, and p is thee integer 1, and q is thee integer zero, 1, or 2, e) A3 is -(CH2)~Het in which Het is a pyrrolidine or piperidine which is unsubstituted or substituted independently of one another once, twice or three times by R1, A4 is absent and A5 is as defined under d ), where A5 is bonded to the nitrogen atom of A3, p is the integer 1, and ris the integer zero, 1, 2 or 3, f) A3 is -CH2-phenyl, where phenyl iss unsubstituted or substituted indepe ndently of one another once, twice ©r three times by R1, Ad is -O-, AS is phenyl, where phenyl is unsubstitut ed or substituted independently of one anothe r once, twice or three times by R1, where R1 is a) phenyl where phenyl is unsubstituteed or substituted independently of one another once, twice or three times by -(C1-C4)-alkyl, b) triazolyl or pyridinyl, Cc) —(C1-C4)-alkyl, d) —(C3-Cg)-cycloalkyl, e) —CF3, f) —~0-CF3,
. : g) fluorine or i) chlo rine, where R2 iss hydrogen atom or -(C1-C3)-allyl in which is alkyl is unssubstituted or substituted independently of one another once, twice or three times by R1, where R3, R6 and R7 are identical or different are i ndependently of one another a) -(C1 -Cg)-alky! in which alkyl is unsubstituted or substituted indeependently of ore another once, twice or three tirmes by R1, b) pheryl in which phenyl is unsubstitutezd or substituted independently of one another once, twice or three times by R1, c) hydreogen atom, or d) -(C3—Ceg)-cycloalkyl in which cycloalky 1 is unsubstituted or substituted independently of one another once, twice or three times by R1, where R4 asd R5 are identical or different ar=e independently of one arother a) -(C4—Cg)-alkyl or -(C,-Cs)-alkenyl, in which alkyl or alkenyl is urisubstituted or su bstituted independently of one arother once, twice or three= times by R1, b) phen-yl in which phenyl is unsubstituteed or substituted independ ently of one another once, twice or three times by IR1, Cc) hydrogen atom, or d) -(C3-#Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted indep-endently of one another once, twice or three times by R1, Yis 2) the radical of a pyrrolidin-2-one whe=re the radical is substituteed in each case by R8 on the nitrogen atom, where R8 iis a) -(C4-Cg)-alkyl in which alkyl is unsubstituted or substituted inde pendently of one2 another once, twice or three tim es by R1, b) phenyl in which phenyl is unsubstituted or substituted independently of one anoth er once, twice or three times by R1, c) -(C3-Cg)-cycloalky! in which cycloalkyl is unsubstituted or substituted independently of one another once, twi ce or three times by R1, Yis 3)the radical of the formula V where R12 is hydrogen atom or -(C1-Cg)-alkyB® in which alkyl is unsubstituted or substituted independently of one another once, twice or three tines by R1, and
® 94 R13 is -CH(R8)-R9 where R8 and R39 are independently of one another phenyl or pyridyl in whi ch pyridyl and phenyl are each wunsubstituted or substituted independent! y of one another once, twice or three times by R1, and R16, R17, R18 and R19 are identical or different ame d are independently of one another 1) hydroegen atom, 2) -(C1-C3)-alkyl in which alkyl is unsubsstituted or substituted twice by R1, or 3) -(Co- Ca)-alkyl-phenyl, in which alkyl &and phenyl are each unsubmstituted or substituted independently of one another once, twice =or three times by R1, and Zis 1) hydrogen atom, 2) ~(C1-Ce)-alky, 3) -(C1-Cp)-alkyl-OH, 4) -(Co-C4)-alkyl -(C3-Cg)-cycloalkyl, or 5) -(C1-C1p)-alkyl-O-C(0)-O-(C3-Cg)-cy cloalkyl.
5. A compound of the formula la as claimed in one or rmore of claims 1 to 4, where Uis hydrogen ato m, X is the radical of the formula Il in which m is the integer 1, Alis -(CH»)-, A2is the radical N which is unsubsstituted or substituted independently of ones another once, twice or three tirmes by F, CI, Br, | or -CH3, Yis 1)theradical of the formula lll where a) A3 is -(C3-Cgg)-cycloalkyl in which cycloalkyl iss unsubstituted or substitutezd independently of one another once, twice or three times by R1, and A4 and AS are absent, b) A3 is -(C2-C4 )-alkynylene in which alkynylene= is unsubstituted or substituted independently of one another once, twice or three times by R1, and A4 and AS are absert, c) A3 is cyclic armine having 3 to 6 ring atoms in which cyclic amine is unsubstituted or subsstituted independently of one an«other once, twice or three
95 n-2006/ 07668 ® times by R1, amd A4 and A5 are absent, d) A3 is -(CCHp)g-phenyl in which phenyl is unsubstituted or substituted independently «of one another once, twice or th ree times by R1, A4 is -N(R2)- im which R2 is as defined below, AbSis a)l) -«C(0)-R3, a)2) -«C(O)-N(R4)-R5, a)3) -«SO2)-R6 or a)4) -cC(O)-0-R7, ois the integer 1, p is the integer 1, and q is the integer zero, 1, or 2, e) A3 is -(CHp)-Het in which Het is a pyrrolidine or piperidine which is unsubstituted o=r substituted independently of osne another once, twice or three times by R1, A4 is absent armd AS is as defined under d), wh ere A5 is bonded to the nitrogen atom of A3, p is the integer 1, and ris the integer =ero, 1, 2 or 3, f) A3 is -CHi2-phenyl, where phenyl is unsubstituted or substituted independently of one another once, twic e or three times by R1, Ad is -O-, A5 is phenyl, vvhere phenyl is unsubstituted or substituted independenti-y of one another once, twice or three times by RE, where R1 is a) phenyl where phenyl is unsubstituted or substituted independentiy= of one another once, twice or three times by -(C1-C4)-alkyl, b) pyridyl or— tetrazolyl, c) -(C1-C4)—alkyl, d) -(C3-Cg)—cycloalkyl, e) -CF3, f) -O-CF3, a) fluorine oer i) chlorine,
® 96 wher-e R2 is hydrogen atom or -(C1-C3)-alkyl in which is alkyl is unsubst ituted or subs tituted independently of one another once, twice or three times by RR1, where R3, R6 and R7 are identical or dif ferent are independently of one another a) (C1-Cg)-alkyl in which alkyl is unsubstituted or substituted indepe=ndently of one znother once, twice or three times by R1, b) phenyl in which phenyl is unsubstituted or substituted independertly of one another once, twice or three times by R1, or Cc) -(C3-Cg)-cycloalkyl, in which cycloalkyl is unsubstituted or substit uted indepoendently of one another once, twice or three times by R1, where R4 and R5 are identical or different are independently of one another a) (C1-Cg)-alkyl or -(C,-Ceg)-alkenyl, in which alkyl or -(C,-Cg)-alkenywl is unsubstituted or substituted independently of one another once, twice or three timess by R1, b) phenyl in which phenyl is unsubstituted or substituted independertly of one another once, twice or three times by R1, Cc) hydrogen atom, or d) -(C3-Cg)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, Y is 2) the radical of a pyrrolidin-2-one where the radical is substituted in each case by R8 on the nitrogen atom, wher-e R8 is phenyl in which phenyl is unsubstituted or substituted indep endently of one another once, twice or threxe times by R1, Yis 3) the radical of the formula V wh ere R12 fis hydrogen atom or -(C1-Cg )-alkyl in which alkyl is unsubstit uted or substituted independently of one another once, twice or three times by R1, and R13 us -CH(R8)-R9 where R8 and R9 are independently of one arother phen yi or pyridyl in which pyridyl and phenyl are each unsubstituted or saubstituted independently of one another once, twice or three times by R1, R16, R17, R18 and R19 are identical or different and are independently of one another 1) hydrogen atom, 2) -(C4-C3)-alkyl in which alkyl is unsubstituted or substituted once or twice by R1, or 3) -(Cg- C3)-alkyl-phenyl, in which alkyl and phenyl are each unsubsstituted or
® substitutead independently of one another onece, twice or three times b=y R1, and Z is hydreogen atom.
6. A compo und of the formula | as claimed in o ne or more of claims 1 to 5, which is the compeound 3-(6-Amiropyridin-3-yl)-2-(1-cyclohexyl-1H-imi dazol-4-yl)propionic acid, Methyl 3- (6-aminopyridin-3-yi)-2-(1-cyclohexyl—1H-imidazol-4-yl)propionaate, Isopropyl 3-(6-aminopyridin-3-y!)-2-(1-cyclohexyl-1H-imidazol-4-yl)propiomnate, Cyclopropylmethyl 3-(6-aminopyridin-3-yl)-2-(1 -cyclohexyl-1H-imidazol-4 - yl)propiorate, 2-Hydroxwyethyl 3-(6-aminopyridin-3-yl)-2-(1-cy clohexyl-1H-imidazol-4-yl)goropionate, 1-Cycloheaxyloxycarbonyloxyethy! 3-(6-aminopwyridin-3-yl)-2-(1-cyclohexyl -1H- imidazol-=1-yl)-propionate, 3-(6-Amiropyridin-3-yl)-2-(1-cyclopentyl-1H-i midazol-4-yl)propionic ac=id, 3-(6-Amiropyridin-3-yl)-2-(1-piperidin-4-yi-1H-imidazol-4-y!)propionic &cid, 3-(6-Amiropyridin-3-yi)-2-[1-(2-oxo-1-phenylpyrrolidin-3-yl)-1H-imidazeol- 4-yl]propi onic acid, 3-(6-Amiropyridin-3-yl)-2-{1-[(benzhydrylcartoamoyl)methyl]-1H-imida=ol- 4-yl}propi onic acid, Isopropyl 3-(6-aminopyridin-3-yl)-2-{1-[(benzydrylcarbamoyl)methyl]- 1H- imidazol-=4-yl}-propionate, 3-(6-Amirmopyridin-3-yl)-2-{1-[4-(3-phenylureicdo)phenyl]-1H-imidazol-4—yl}propionic acid, 3-(6-Amirmopyridin-3-yl)-2-{1-[2-(1-diphenylac«etylpiperidin-4-y)ethyl]-1 FH-imidazol- 4-yl}-prop ionic acid, 3-(6-Amirmopyridin-3-yl)-2-{1-[2-(1-benzoylpipeeridin-4-yl)ethyl]-1H-imid=azol- 4-yl}propiconic acid, 3-(6-Amirmopyridin-3-yl)-2-[1-(1-benzoylpiperidin-2-yimethyl)-1H-imidaz=ol- 4-yllpropicnic acid, 3-(6-Aminuopyridin-3-yl)-2-(1-{2-[1-(3-phenylpr-opionyl)piperidin-3-yl]eth=y}-1H- imidazol-4-yl)propionic acid, 3-(6-Amin opyridin-3-yl)-2-[1-(1-diphenylacetyl piperidin-3-yimethyl)-1H- imidazol- 4-yl]propiconic acid, 3-(6-Amin opyridin-3-yl)-2-(1-{2-[1-(3-phenylpropionyl)piperidin-4-yl]ethxyl}- 1H- imidazol-4--yl)propionic acid, 3-(6-Amin opyridin-3-yl)-2-{1-[2-(1-phenylacety/ipiperidin-3-yl)ethyl]-1H-i midazol-
® 98 4-yl}propionic aci d, 3-(6-Aminopyridir-3-yl}-2-{1-[2-(1-phenylacetylpipe ridin-4-yl)ethyl]-1H-imidazol- 4-yl}propionic aci d, 3-(6-Aminopyridir-3-yl)-2-{1-[1-(4'-methylbiphenyl-3-carbonyl)piperidin-
4-yimethyl]-1H-inmidazol-4-yl}propionic acid, 3-(6-Aminopyridim-3-yl)-2-[1-(1-benzoylpiperidin-4-yimethyl)-1H-imidazol- 4-yl]propionic acid, 3-(6-Aminopyridir-3-yl)-2-(1-benzhydryl-1H-imidazol-4-yl)propionic acid, 3-(6-Aminopyridim-3-yl)-2-{1-(4-[1,2,4]triazol-1-yl-be nzyl)-1H-imidazol-
4-yl]propionic acid, 3-(6-Aminopyridirm-3-y!)-2-[1-(4-trifluoromethoxyben _zyl)-1H-imidazol-4-yl]propionic acid, 3-(6-Aminopyridir-3-yl)-2-[1-(1,1-dioxo-1H-1,6-benzo[b}thiophen-2-yimethyl)-1H- imidazol-4-yllpropionic acid, 3-(6-Aminopyridire-3-yl)-2-[1-(5-chlorobenzo[b]thiopien-3-yimethyl)-1H-imidazol- 4-yl}-propionic aci d, 3-(6-Aminopyridire-3-yl)-2-{1-[3-(4-fluorophenoxy)be nzyl]-1H-imidazol- 4-yl}propionic acid, 3-(6-Aminopyridin -3-yl)-2-[1-(2-phenoxybenzyl!)-1H-#midazol-4-yl)propionic acid, 3-(6-Aminopyridin -3-y1)-2-[1-(4-phenoxybenzy!)-1H-&midazol-4-yl}propionic acid, 3-(6-Aminopyridin -3-yl)-2-(1-prop-2-ynyl-1H-imidazol-4-yl)propionic acid, 3-(6-Aminopyridin -3-y!)-2-(1-but-2-ynyl-1H-imidazol—4-yl)propionic acid, 3-(6-Aminopyridin -3-y!)-2-[1-(4,4-dimethylcyclohexyl )-1H-imidazol-4-yl]propionic acid, 3-(6-Aminopyridin—3-yl)-2-{1-[(benzhydrylmethyicarb amoyl)methyl}-1H-imidazol- 4-yi}- propionic ac id, 3-(6-Aminopyridin—-3-yl)-2-[1-({[(4-chlorophenyl)phen ylmethyljcarbamoyl}methyl)- 1H- imidazol-4-yl]poropionic acid, 3-(6-Aminopyridin—3-y1)-2-[1-({[bis-(4-methoxyphenyl )methyllcarbamoyl}methyl)- 1H-imidazol-4-yl]p ropionic acid, 3-(6-Aminopyridin—3-yl)-2-{1-[4-(3-propylureido)phen yl]-1H-imidazol-4-yl}propionic acid, 3-(6-Aminopyridin—3-yl)-2-{1-[4-(toluene-4-sulfonylanino)phenyl]- 1H-imidazol- 4-yl}-propionic acid, 3-(6-Aminopyridin- 3-yl)-2-{1-[3-(3-propylureido)benzwyl]- 1H-imidazol-4-yl}propionic acid,
® 99 Er2006/ 078 BE 3-(6-Aminopyridin-3-wl)-2-{1-[3-(3-phenethylureido)benz yl]-1H-imidazol- 4-yl}propionic acid, 3-(6-Aminopyridin-3-wl)-2-{1-[3-(3-benzylureido)benzyl]- 1H-imidazol-4-yl}propioni c acid, 3-(6-Aminopyridin-3-y/1)-2-{1-[3-(3-vinylureido)benzyl]-1H-imidazol-4-yl}propionic acid, 3-(2-Aminothiazol-4-y1)-2-{1-[(benzhydrylcarbamoyl)met hyl]-1H-imidazol-4-yl- : propionic acid, 3-(2-Aminothiazol-4-y~1)-2-[1-({{(4-chlorophenyl)phenylmethyl]carbamoyl}methyl)- 1H-imidazol-4-yl]prop ionic acid, 3-(6-Aminopyridin-3-y~1)-2-{1-[4-(3-tert-butylureido)pheny I]-1H-imidazol-4-yl}- propionic acid, 3-(6-Aminopyridin-3-y-1)-2-{1-[4-(3-benzylureido)pheny!}- 1 H-imidazol-4-yl}propioniac acid or Ethyl 3-(6-aminopyridi n-3-yl)-2-(1-cyclohexyl-1H-imidazo I-4-yl)propionate.
7. A process for preparireg the compound of the formula | as claimed in one or more of claims 1 to 6, whicte comprises a), a compound of the formula Vil Sm (vi) PG—O N where PG1 is a carboxyl protective group, being converted into a compound of the formula | as claimexd in claim 1, b) a compound of the formula | which has been prepared by process a), or a suitable precur sor of the formula | which occurs o wing to its chemical structure in enantiomeric forms being fractionated by salt formation with enantiopure acids or bases, chromatography on chiral stationary phases or derivatization using chi ral enantiopure compounds such a's amino acids, separation of the diasteereomers obtained in this way, and elimination of the chiral auxiliary groups into thes pure enantiomers, or Cc) the compound of the formula | prepared by processes a) or b) being either isolated in free form or, in the case where acidic or basic gyroups are present, converted into physiologically tolerated salts.
® 100
8. As medicament having an effectiv-e content of at least one compound of the formula | as claimed in one or moore of claims 1 to 6 together with a p harmaceutically suitable and phe ysiologically tolerated carrier, additive and/or 0 ther active ingredients and excipients.
9. T he use of the compound of the formula | as claimed in one or rmore of claims 1 tc 6 for producing a medicament for the prophylaxis and therapy of all disorders associated with thromboses, emibolisms, hypercoagulability or fi brotic changes.
10. Tihe use as claimed in claim 9, which is applied to myocardial infarction, angina pe=ctoris and other types of acute coronary syndrome, stroke, pe ripheral vascular di sorders, deep vein thrombosis, pulmonary embolism, embolic or thrombotic ewents caused by cardiac arrhyth mias, cardiovascular events su ch as restenosis following revascularization and amgioplasty and similar proceduress such as stent implantations and bypass operations, or reduction of the risk of t hrombosis fo-llowing surgical procedures as i n knee and hip joint operations , or disseminated in—travascular coagulation, sepsis and other intravascular events “which are asssociated with an inflammation, atherosclerosis, diabetes and tke metabolic syndrome and its sequelae, tumo r growth and tumor metastasis, impairments of thee hemostatic system such as fitorin deposits, fibrotic changes o»f the lung such ass chronic obstructive lung diseasse, adult respiratory distress syrndrome or fibrin de=posits in the eye after eye operations or prevention and/or treamtment of scar fomrmation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004020186A DE102004020186A1 (en) | 2004-04-22 | 2004-04-22 | Heterocyclyl acetic acids as inhibitors of TAFla |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200607668B true ZA200607668B (en) | 2008-03-26 |
Family
ID=34964308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200607668A ZA200607668B (en) | 2004-04-22 | 2006-09-13 | Imidazole derivatives used as tafia inhibitors |
Country Status (34)
| Country | Link |
|---|---|
| EP (2) | EP1740569B1 (en) |
| JP (1) | JP4939401B2 (en) |
| KR (1) | KR101162047B1 (en) |
| CN (1) | CN100572376C (en) |
| AR (1) | AR053302A1 (en) |
| AT (2) | ATE386737T1 (en) |
| AU (1) | AU2005238144B2 (en) |
| BR (1) | BRPI0510159A (en) |
| CA (1) | CA2563401C (en) |
| CR (1) | CR8650A (en) |
| CY (1) | CY1108087T1 (en) |
| DE (2) | DE102004020186A1 (en) |
| DK (1) | DK1740569T3 (en) |
| EC (1) | ECSP066941A (en) |
| ES (1) | ES2299026T3 (en) |
| HR (1) | HRP20080099T3 (en) |
| IL (1) | IL178672A (en) |
| MA (1) | MA28543B1 (en) |
| MY (1) | MY140903A (en) |
| NI (1) | NI200600217A (en) |
| NO (1) | NO20065320L (en) |
| NZ (1) | NZ550757A (en) |
| PE (1) | PE20060172A1 (en) |
| PL (1) | PL1740569T3 (en) |
| PT (1) | PT1740569E (en) |
| RS (1) | RS50553B (en) |
| RU (1) | RU2375356C2 (en) |
| SI (1) | SI1740569T1 (en) |
| TN (1) | TNSN06341A1 (en) |
| TW (1) | TWI359016B (en) |
| UA (1) | UA87306C2 (en) |
| UY (1) | UY28868A1 (en) |
| WO (1) | WO2005105781A1 (en) |
| ZA (1) | ZA200607668B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150514T1 (en) * | 2006-12-06 | 2015-09-11 | Sanofi | KAO SULFAMIDE DERIVATIVES TAFIa INHIBITORS |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| WO2008100459A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
| CN102056922B (en) | 2008-06-06 | 2013-11-20 | 赛诺菲-安万特 | Macrocyclic urea and sulfonamide derivatives as TAFIA inhibitors |
| JPWO2010050525A1 (en) | 2008-10-29 | 2012-03-29 | 大正製薬株式会社 | Compound having TAFIa inhibitory activity |
| BRPI1010571A2 (en) * | 2009-05-15 | 2019-09-24 | Sanofi Sa | process for the preparation of a compound useful as a taffla inhibitor. |
| FR2947266B1 (en) * | 2009-06-26 | 2011-06-17 | Servier Lab | NOVEL 2-MERCAPTOCYCLOPENTANECARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| WO2011041154A1 (en) | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| ES2643132T3 (en) * | 2010-03-18 | 2017-11-21 | Daiichi Sankyo Company, Limited | Imidazole substituted cycloalkyl derivative |
| EP2548872B1 (en) | 2010-03-18 | 2016-09-28 | Daiichi Sankyo Company, Limited | Cyclopropanecarboxylic acid derivative |
| EP2638016B1 (en) | 2010-11-11 | 2014-10-01 | Sanofi | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives |
| US9145385B2 (en) | 2011-11-25 | 2015-09-29 | Sanofi | Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid |
| US9102657B2 (en) * | 2011-11-25 | 2015-08-11 | Sanofi | Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid |
| WO2013076177A1 (en) | 2011-11-25 | 2013-05-30 | Sanofi | Salt of (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl) ethyl propionate |
| EP2805705B1 (en) | 2013-05-23 | 2016-11-09 | IP Gesellschaft für Management mbH | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid |
| BR112015029667A2 (en) | 2013-06-10 | 2017-07-25 | Sanofi Sa | macrocyclic urea derivatives as tafia inhibitors, their preparation and their uses as pharmaceuticals |
| US20190117624A1 (en) | 2016-03-29 | 2019-04-25 | Daiichi Sankyo Company, Limited | Therapeutic agent for inflammatory bowel diseases |
| CA3032432A1 (en) | 2016-08-03 | 2018-02-08 | Charles A. Mcwherter | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2292262T3 (en) * | 1998-12-24 | 2008-03-01 | Astellas Pharma Inc. | IMIDAZOL COMPOUNDS AND THEIR MEDICINAL USE. |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| MXPA04005940A (en) | 2002-01-22 | 2004-09-13 | Pfizer | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases. |
-
2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/en not_active Withdrawn
-
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/en not_active Application Discontinuation
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/en not_active IP Right Cessation
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/en not_active Expired - Fee Related
- 2005-04-07 SI SI200530185T patent/SI1740569T1/en unknown
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/en not_active Expired - Fee Related
- 2005-04-07 AT AT05731221T patent/ATE386737T1/en active
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/en not_active Expired - Lifetime
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/en unknown
- 2005-04-07 PL PL05731221T patent/PL1740569T3/en unknown
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 AT AT07017340T patent/ATE523505T1/en active
- 2005-04-07 PT PT05731221T patent/PT1740569E/en unknown
- 2005-04-07 ES ES05731221T patent/ES2299026T3/en not_active Expired - Lifetime
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/en not_active Ceased
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/en not_active Expired - Fee Related
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/en not_active Application Discontinuation
- 2005-04-07 EP EP05731221A patent/EP1740569B1/en not_active Expired - Lifetime
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/en unknown
- 2005-04-07 DK DK05731221T patent/DK1740569T3/en active
- 2005-04-07 EP EP07017340A patent/EP1864979B1/en not_active Expired - Lifetime
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-20 TW TW094112493A patent/TWI359016B/en not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/en not_active Application Discontinuation
- 2005-04-22 UY UY28868A patent/UY28868A1/en unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/en unknown
-
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/en unknown
- 2006-09-22 CR CR8650A patent/CR8650A/en unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/en unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/en unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/en not_active Application Discontinuation
-
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200607668B (en) | Imidazole derivatives used as tafia inhibitors | |
| US6403595B1 (en) | Sulfonamide derivatives, processes for producing the same and utilization thereof | |
| EP3421036B1 (en) | Multisubstituted aromatic compounds as serine protease inhibitors | |
| JP4585448B2 (en) | Pyrazole derivatives as factor Xa inhibitors | |
| CA2197471A1 (en) | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | |
| WO2003013526A1 (en) | Anticoagulant compounds | |
| EP1220842A1 (en) | Cyclic amine compounds as ccr5 antagonists | |
| EP1188755B1 (en) | Acylhydrazine derivatives, process for preparing the same and use thereof | |
| US20070129341A1 (en) | Imidazole derivatives used as tafia inhibitors | |
| US5591737A (en) | Substituted azetidinones as anti-inflammatory and antidegenerative agents | |
| JP2000204081A (en) | Sulfonamide derivative, its production and use | |
| MX2007007486A (en) | Novel heteroarylacetamides. | |
| US20040038986A1 (en) | Carbamate derivatives, process for producing the same and use thereof | |
| JPWO1999064392A1 (en) | benzamidine derivatives | |
| MXPA06011067A (en) | Imidazole derivatives used as tafia inhibitors | |
| WO2010005087A1 (en) | Amidine derivative | |
| JP2006527729A (en) | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor XA inhibitors for the treatment of acute vascular disease | |
| JPWO2000078747A1 (en) | Acylhydrazine derivatives, their production method and uses | |
| JPWO1999040075A1 (en) | Sulfonamide derivatives, their production method and use | |
| HK1101823B (en) | Imidazole derivatives used as tafia inhibitors | |
| MXPA99012069A (en) | Novel n-substituted urea inhibitors of farnesyl-protein transferase | |
| JPWO1999047503A1 (en) | Aminoisoquinoline Derivatives |